|
<?xml version="1.0" encoding="UTF-8" standalone="yes"?> |
|
<tmx version="1.4"> |
|
<header adminlang="en" creationdate="20200424T153632Z" creationtool="mALIGNa" creationtoolversion="2" datatype="plaintext" o-tmf="al" segtype="block" srclang="lv"> |
|
<prop type="distributor">ELRC project</prop> |
|
<prop type="description">Acquisition of bilingual data (from multilingual websites), normalization, cleaning, deduplication and identification of parallel documents have been done by ILSP-FC tool. Maligna aligner was used for alignment of segments. Merging/filtering of segment pairs has also been applied.</prop> |
|
<prop type="l1">lv</prop> |
|
<prop type="l2">en</prop> |
|
<prop type="lengthInTUs">520</prop> |
|
<prop type="# of words in l1">7825</prop> |
|
<prop type="# of words in l2">6543</prop> |
|
<prop type="# of unique words in l1">1555</prop> |
|
<prop type="# of unique words in l2">2173</prop> |
|
</header> |
|
<body> |
|
<tu tuid="1"> |
|
<prop type="lengthRatio">0.9777777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The person is also at risk of complications.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šādam cilvēkam pastāv arī komplikāciju risks.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="2"> |
|
<prop type="lengthRatio">1.2857142857142858</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is called the antigen.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>To dēvē par antigēnu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="3"> |
|
<prop type="lengthRatio">1.0161290322580645</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Immunity usually lasts for years, and sometimes for a lifetime.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Imunitāte parasti saglabājas gadiem un reizēm pat mūža garumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="4"> |
|
<prop type="lengthRatio">0.85</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How vaccines work</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā vakcīnas darbojas</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="5"> |
|
<prop type="lengthRatio">0.8604651162790697</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This ‘ community immunity ' can only work if enough people are vaccinated.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šī "kolektīvā imunitāte" darbojas tikai tad, ja ir vakcinēti pietiekami daudz cilvēku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="6"> |
|
<prop type="lengthRatio">1.03125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines contain a greatly weakened or an inactivated (killed) form of a virus or bacterium that usually causes a disease, or a small part of the virus or bacterium.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas satur ļoti novājinātu vai inaktivētu (nonāvētu) tā vīrusa vai baktērijas formu, kas parasti izraisa saslimšanu, vai nelielu vīrusa vai baktērijas daļu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="7"> |
|
<prop type="lengthRatio">0.9285714285714286</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The length of time varies by disease and by vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Saglabāšanās ilgums ir atkarīgs no slimības un vakcīnas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="8"> |
|
<prop type="lengthRatio">1.0170454545454546</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Immunity through vaccination protects not only the immunised individual but also protects unvaccinated people in the community, such as infants who are too young to be vaccinated.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinējoties iegūtā imunitāte aizsargā ne tikai vakcinēto cilvēku, bet arī iedzīvotāju vidū esošos nevakcinētos cilvēkus, piemēram, zīdaiņus, kuri vakcinācijai ir pārāk jauni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="9"> |
|
<prop type="lengthRatio">1.0328947368421053</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It will then quickly produce the right antibodies and activate the right immune cells to kill the virus or bacterium, protecting the person from the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā ātri izstrādās pareizās antivielas un aktivizēs pareizās imūnsistēmas šūnas, lai tās nonāvē vīrusu vai baktēriju, aizsargājot cilvēku no saslimšanas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="10"> |
|
<prop type="lengthRatio">1.1886792452830188</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Later, if the person comes into contact with the actual infectious virus or bacterium, their immune system will ‘remember' it.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kad cilvēks vēlāk nonāk saskarē ar īstu infekciozu vīrusu vai baktēriju, viņa imūnsistēma to "atcerēsies".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="11"> |
|
<prop type="lengthRatio">1.1717171717171717</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In contrast, a person who becomes immune by getting the disease can expose other unvaccinated people to the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Turpretī cilvēks, kurš iegūst imunitāti slimojot, var pakļaut slimībai citus nevakcinētus cilvēkus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="12"> |
|
<prop type="lengthRatio">0.85</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antibodies are special proteins that help kill the infectious agent.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Antivielas ir īpašas olbaltumvielas, kas palīdz nonāvēt infekcijas ierosinātāju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="13"> |
|
<prop type="lengthRatio">1.3767123287671232</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood, in the bone marrow and all over the body, called T-cells, B-cells, among others.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katrs vīruss un baktērija izraisa unikālu imūnsistēmas reakciju, kurā iesaistīts specifisks šūnu kopums asinīs, kaulu smadzenēs un visā organismā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="14"> |
|
<prop type="lengthRatio">1.3142857142857143</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When a person is given the vaccine, their immune system recognises the antigen as ‘foreign'.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kad cilvēkam ievada vakcīnu, imūnsistēma atpazīst antigēnu kā "svešu".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="15"> |
|
<prop type="lengthRatio">1.367816091954023</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine stimulates an immune response, and a ‘memory' of the body to a specific disease, without causing the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīna stimulē imūnreakciju un organisma atmiņu par specifisku slimību, to neizraisot.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="16"> |
|
<prop type="lengthRatio">0.9680851063829787</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The immune cells are trained to kill and make antibodies against the disease-causing agent.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Imūnsistēmas šūnas ir apmācītas nonāvēt slimības ierosinātāju un izstrādāt pret to antivielas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="17"> |
|
<prop type="lengthRatio">1.631578947368421</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas komponenti</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="18"> |
|
<prop type="lengthRatio">0.9090909090909091</prop> |
|
<tuv xml:lang="en"> |
|
<seg>1-4 people</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>1-4 cilvēki</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="19"> |
|
<prop type="lengthRatio">0.88</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Thanks to vaccination:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pateicoties vakcinācijai:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="20"> |
|
<prop type="lengthRatio">1.0405405405405406</prop> |
|
<tuv xml:lang="en"> |
|
<seg>transmission of polio has ended in most parts of the world, including Europe.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>poliomielīta pārnese ir beigusies pasaules lielākajā daļā, tostarp Eiropā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="21"> |
|
<prop type="lengthRatio">0.9427480916030534</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tās palīdz mazināt sociālo, psiholoģisko un finansiālo slogu, ko slimības rada cilvēkiem un valdībām, mazinot spiedienu uz veselības aprūpes un sociālās aprūpes sistēmām un ļaujot cilvēkiem īstenot produktīvas darbības, tostarp izglītības un nodarbinātības jomā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="22"> |
|
<prop type="lengthRatio">0.9811320754716981</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination programmes have wider societal benefits.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācijas programmām ir plašāki sociālie ieguvumi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="23"> |
|
<prop type="lengthRatio">0.924812030075188</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This shows both the most conservative estimate (inner ring, darker dots) and the maximum estimate (outer ring, paler dots).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas parāda gan vispiesardzīgāko aplēsi (iekšējais gredzens, tumšāki punkti), gan maksimālo aplēsi (ārējais gredzens, blāvāki punkti).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="24"> |
|
<prop type="lengthRatio">0.9487179487179487</prop> |
|
<tuv xml:lang="en"> |
|
<seg>smallpox is now eradicated worldwide;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>bakas tagad ir izskaustas visā pasaulē;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="25"> |
|
<prop type="lengthRatio">1.1294117647058823</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When a large percentage of a population is vaccinated, infectious diseases cannot easily spread.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ja liela daļa iedzīvotāju ir vakcinēti, infekcijas slimības nevar viegli izplatīties.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="26"> |
|
<prop type="lengthRatio">1.2823529411764707</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination also prevents the development of certain types of pre-cancerous growths and cancers, for example:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija novērš arī noteiktu pirmsvēža augšanas un vēža veidu attīstību, piemēram:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="27"> |
|
<prop type="lengthRatio">1.2213740458015268</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The connected dots indicate the maximum and minimum number of previously uninfected and unvaccinated people who could get infected by a person with the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Saistītie punkti norāda iepriekš neinficēto un nevakcinēto cilvēku maksimālo un minimālo skaitu, kuri varētu inficēties ar slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="28"> |
|
<prop type="lengthRatio">0.9021739130434783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination can eliminate diseases or reduce the number of new cases significantly.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija var novērst slimības vai ievērojami samazināt jaunu inficēšanās gadījumu skaitu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="29"> |
|
<prop type="lengthRatio">1.05</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination helps prevent the spread of disease in communities.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija palīdz novērst slimības izplatīšanos sabiedrībā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="30"> |
|
<prop type="lengthRatio">1.2328767123287672</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination prevents people from getting the symptoms of the disease, which can be severe.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija neļauj cilvēkiem iegūt slimības simptomus, kas var būt smagi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="31"> |
|
<prop type="lengthRatio">0.9527027027027027</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination is the best way to acquire immunity against vaccine-preventable diseases, as opposed to immunity attained by getting the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija ir labākais veids, kā iegūt imunitāti pret vakcīnregulējamām slimībām, salīdzinājumā ar imunitāti, kas iegūta, saslimstot ar šo slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="32"> |
|
<prop type="lengthRatio">1.0297029702970297</prop> |
|
<tuv xml:lang="en"> |
|
<seg>vaccinating against hepatitis B can help prevent liver cancer caused by long-term hepatitis B infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>vakcinācija pret B hepatītu var palīdzēt novērst aknu vēzi, ko izraisa ilgstoša B hepatīta infekcija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="33"> |
|
<prop type="lengthRatio">0.8846153846153846</prop> |
|
<tuv xml:lang="en"> |
|
<seg>vaccinating against humanpapilloma virus (HPV) can help prevent cervical and other cancers caused by HPV infection;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>vakcinācija pret cilvēka papilomas vīrusu (HPV) var palīdzēt novērst dzemdes kakla un citus vēža veidus, ko izraisa HPV infekcija;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="34"> |
|
<prop type="lengthRatio">2.375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>To dēvē par kolektīvo imunitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="35"> |
|
<prop type="lengthRatio">1.0545454545454545</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The centre dot represent one person affected by a disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Centrālais punkts ir viens ar slimību inficēts cilvēks.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="36"> |
|
<prop type="lengthRatio">0.9354838709677419</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Safety, quality and standards</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Drošums, kvalitāte un standarti</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="37"> |
|
<prop type="lengthRatio">1.1384615384615384</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The first vaccine was developed in the 18th century in the United Kingdom.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pirmā vakcīna tika izstrādāta 18. gadsimtā Apvienotajā Karalistē.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="38"> |
|
<prop type="lengthRatio">0.8780487804878049</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The last known naturally occurring case was recorded in 1977 in Somalia.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pēdējais zināmais dabiskas izcelsmes gadījums tika reģistrēts 1977. gadā Somālijā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="39"> |
|
<prop type="lengthRatio">0.7666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccinating</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācijas sniegtie ieguvumi</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="40"> |
|
<prop type="lengthRatio">0.9873417721518988</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine is continuously monitored to ensure it remains safe and effective.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu pastāvīgi uzrauga, lai nodrošinātu, ka tā vienmēr ir droša un efektīva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="41"> |
|
<prop type="lengthRatio">1.0195121951219512</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine can only be approved for use in the European Union (EU) and European Economic Area (EEA) after a scientific evaluation of the results of these tests to ensure its quality, safety and effectiveness.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu var apstiprināt lietošanai Eiropas Savienībā (ES) un Eiropas Ekonomikas zonā (EEZ) tikai pēc šo pārbaužu rezultātu zinātniska novērtējuma, lai garantētu vakcīnas kvalitāti, drošumu un efektivitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="42"> |
|
<prop type="lengthRatio">1.2692307692307692</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They also help to prevent the spread of diseases in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tās arī palīdz novērst slimību izplatīšanos kopienā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="43"> |
|
<prop type="lengthRatio">1.1058823529411765</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Only then, after approval, can a vaccine be manufactured, marketed and used to protect people.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tikai pēc apstiprināšanas vakcīnu var ražot, tirgot un izmantot cilvēku aizsardzībai.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="44"> |
|
<prop type="lengthRatio">0.9918032786885246</prop> |
|
<tuv xml:lang="en"> |
|
<seg>As with any medicine, some people may experience side effects from a vaccine, but these are usually mild and short-lived.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā ar jebkurām zālēm, dažiem cilvēkiem no vakcīnas var rasties blakusparādības, taču tās parasti ir vieglas un īslaicīgas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="45"> |
|
<prop type="lengthRatio">0.8529411764705882</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They mainly target diseases caused by viruses or bacteria.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tās galvenokārt cīnās pret vīrusu vai baktēriju izraisītām slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="46"> |
|
<prop type="lengthRatio">0.9447513812154696</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The scientific experts evaluating vaccines always consider the benefits and any potential risks very carefully, in particular because vaccines are given to healthy people.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Zinātniskie eksperti, kuri novērtē vakcīnas, vienmēr ļoti rūpīgi ņem vērā ieguvumus un jebkādus potenciālos riskus, galvenokārt tāpēc, ka vakcīnas tiek ievadītas veseliem cilvēkiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="47"> |
|
<prop type="lengthRatio">0.875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Serious side effects are very rare.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Smagas blakusparādības novēro ļoti reti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="48"> |
|
<prop type="lengthRatio">0.9722222222222222</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They can include mild fever, or pain or redness at the injection site.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tās var ietvert nelielu drudzi vai sāpes vai apsārtumu injekcijas vietā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="49"> |
|
<prop type="lengthRatio">0.9791666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Nowadays, there are vaccines for many diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Mūsdienās pastāv vakcīnas pret daudzām slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="50"> |
|
<prop type="lengthRatio">1.09</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are used worldwide as a highly effective way to protect people from contracting infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas visā pasaulē izmanto kā ļoti efektīvu līdzekli cilvēku aizsardzībai no infekcijas slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="51"> |
|
<prop type="lengthRatio">1.0495867768595042</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines work by ‘teaching' a person's immune system (the body's natural defences) to defend itself against a specific disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas darbojas, "apmācot" cilvēka imūnsistēmu (organisma dabīgo aizsargsistēmu) pašaizsardzībai pret konkrētu slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="52"> |
|
<prop type="lengthRatio">1.0151515151515151</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This evaluation needs to show that a vaccine's benefits in protecting people against diseases are far greater than any potential risk.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šim novērtējumam jāapliecina, ka vakcīnas ieguvumi cilvēku aizsardzībai no slimībām pārliecinoši pārsniedz jebkādu potenciālo risku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="53"> |
|
<prop type="lengthRatio">1.0694444444444444</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Recently, a vaccine was developed against Ebola virus disease, and research is underway on vaccines to protect against human immunodeficiency virus (HIV).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Nesen tika izstrādāta vakcīna pret Ebolas vīrusslimību, un tiek veikti pētījumi, lai izstrādātu vakcīnas pret cilvēka imūndeficīta vīrusu (HIV).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="54"> |
|
<prop type="lengthRatio">1.0441176470588236</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Before any new vaccine can be used, it has to undergo rigorous testing.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pirms katras jaunas vakcīnas lietošanas tai veic stingras pārbaudes.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="55"> |
|
<prop type="lengthRatio">1.1304347826086956</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It was a vaccine against smallpox, a deadly disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā bija vakcīna pret nāvējošu slimību - bakām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="56"> |
|
<prop type="lengthRatio">0.8493150684931506</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Research is ongoing to develop vaccines against more diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tiek veikti pētījumi, lai izstrādātu vakcīnas pret vēl vairākām slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="57"> |
|
<prop type="lengthRatio">0.8414634146341463</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Mūsdienās bakas cilvēku vidū visā pasaulē ir izskaustas, pateicoties vakcinācijai.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="58"> |
|
<prop type="lengthRatio">0.8823529411764706</prop> |
|
<tuv xml:lang="en"> |
|
<seg>More factsheets</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vairāk faktu lapu</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="59"> |
|
<prop type="lengthRatio">0.9473684210526315</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāka informācija pieejama ECDC tīmekļa vietnē: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="60"> |
|
<prop type="lengthRatio">1.2114285714285715</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piezīme: šīs faktu lapas informācija ir paredzēta vispārīgas informēšanas nolūkos, un ar to nedrīkst aizstāt veselības aprūpes speciālista individuālu ekspertīzi un spriedumu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="61"> |
|
<prop type="lengthRatio">0.9690721649484536</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Symptoms usually appear 7 to 10 days after infection, but may also appear up to 21 days later:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Simptomi parasti parādās 7 līdz 10 dienas pēc inficēšanās, bet var parādīties arī 21 dienu vēlāk.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="62"> |
|
<prop type="lengthRatio">0.8762886597938144</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antibiotics can be used to treat pertussis and prevent further spread of the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Antibiotikas var izmantot, lai ārstētu garo klepu un novērstu šīs slimības turpmāku izplatīšanos.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="63"> |
|
<prop type="lengthRatio">1.2210526315789474</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A third or fourth dose is recommended at 11-24 months of age, and another dose between three and seven years of age.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Trešā vai ceturtā deva ir ieteicama 11-24 mēnešu vecumā un vēl viena deva 3 līdz 7 gadu vecumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="64"> |
|
<prop type="lengthRatio">1.3663366336633664</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A primary course of 2-3 doses is usually given between two and twelve months of age, in accordance with the national vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sākotnējo 2-3 devu kursu parasti ievada 2 līdz 12 mēnešu vecumā saskaņā ar valsts vakcinācijas plānu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="65"> |
|
<prop type="lengthRatio">0.8953488372093024</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some EU/EEA countries recommend boosters for adolescents, adults, and/or women during pregnancy, which also temporarily protects the baby once it is born.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažas ES/EEZ valstis iesaka ievadīt atkārtotas vakcīnas pusaudžiem, pieaugušajiem un/vai sievietēm grūtniecības laikā, kas arī īslaicīgi aizsargā bērnu pēc tā piedzimšanas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="66"> |
|
<prop type="lengthRatio">0.9173553719008265</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They initially occur at night and then become more frequent during the day and may recur for one to two months.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sākotnēji klepus lēkmes notiek naktī un tad kļūst biežākas dienas laikā, un tās var atkārtoties vienu līdz divus mēnešus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="67"> |
|
<prop type="lengthRatio">1.1125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, in order to be most effective, treatment must begin early in the course of disease, during the first one to two weeks before the episodes of numerous rapid coughs occur.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr, lai ārstēšana būtu visefektīvākā, tā jāuzsāk agrīnā slimības stadijā, pirmajā nedēļā vai divu nedēļu laikā pirms daudzu straujo klepus lēkmju iestāšanās.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="68"> |
|
<prop type="lengthRatio">0.9137931034482759</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Adolescents, adults, or children partially immunised generally have milder or somewhat different symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pusaudžiem, pieaugušajiem vai bērniem, kuri ir daļēji imunizēti, parasti ir vieglāki vai nedaudz atšķirīgi simptomi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="69"> |
|
<prop type="lengthRatio">1.1626016260162602</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis can also be spread by an individual who has only a mild form of the disease, or by an infected individual who has no symptoms at all.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Garo klepu var izplatīt arī persona, kurai ir tikai viegla slimības forma, vai inficēta persona, kurai vispār nav simptomu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="70"> |
|
<prop type="lengthRatio">1.1159420289855073</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The most important way to prevent pertussis is through complete immunisation.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Visefektīvākais veids, kā novērst saslimšanu, ir pilnīga imunizācija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="71"> |
|
<prop type="lengthRatio">1.047244094488189</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Frequently, older siblings and parents who may be carrying the bacteria bring the disease home and infect an infant in the household.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vecāki brāļi un māsas un vecāki, kuri, iespējams, pārnēsā baktērijas, bieži atnes slimību mājās un inficē bērnu mājsaimniecībā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="72"> |
|
<prop type="lengthRatio">1.0656934306569343</prop> |
|
<tuv xml:lang="en"> |
|
<seg>After this phase, the coughing fits become less frequent and less severe, and the infant gradually gets better (this can take up to three months).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pēc šā posma klepus lēkmes kļūst aizvien retākas un vieglākas, un zīdainis pakāpeniski atveseļojas (tas var ilgt līdz pat trim mēnešiem).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="73"> |
|
<prop type="lengthRatio">1.0555555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In these groups, and in very young infants, pertussis is harder to diagnose.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šajās grupās un ļoti maziem zīdaiņiem ir grūtāk diagnosticēt garo klepu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="74"> |
|
<prop type="lengthRatio">1.1363636363636365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The most severe forms of pertussis are in infants.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vissmagākās garā klepus formas ir zīdaiņiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="75"> |
|
<prop type="lengthRatio">1.053475935828877</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine for pertussis is usually given in combination with diphtheria and tetanus vaccination (often in combination also with poliomyelitis, Haemophilus influenzae and hepatitis B vaccination).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu pret garo klepu parasti ievada kombinācijā ar vakcināciju pret difteriju un stingumkrampjiem (bieži arī kombinācijā ar poliomielīta, Haemophilus influenzae un B hepatīta vakcīnu).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="76"> |
|
<prop type="lengthRatio">1.1007751937984496</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who is not vaccinated with the pertussis vaccine, or whose vaccination status is not up-to-date, is at risk of contracting the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ikvienai personai, kura nav vakcinēta pret garo klepu vai kuras vakcinācijas statuss nav aktuāls, ir risks saslimt ar šo slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="77"> |
|
<prop type="lengthRatio">1.180722891566265</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Komplikācijas ir pneimonija, encefalopātija (smadzeņu slimība), lēkmes un pat nāve.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="78"> |
|
<prop type="lengthRatio">1.083916083916084</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some countries also recommend a booster to unprotected women soon after they have delivered, to reduce the risk of transmission of the disease to the baby.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažas valstis arī iesaka ievadīt atkārtotu vakcīnu neaizsargātām sievietēm drīz pēc dzemdībām, lai samazinātu slimības pārnešanas risku bērnam.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="79"> |
|
<prop type="lengthRatio">1.015267175572519</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In adults and older children, complications include inability to breathe for short periods, broken ribs, rectal prolapse and hernias.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pieaugušajiem un vecākiem bērniem komplikācijas ietver īslaicīgu nespēju elpot, salauztas ribas, taisnās zarnas prolapsu un trūces.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="80"> |
|
<prop type="lengthRatio">1.1333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Within two weeks, the cough becomes more severe and is characterized by episodes of numerous rapid coughs, followed by a crowing or high-pitched ‘whoop'.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Divu nedēļu laikā klepus kļūst spēcīgāks, un tam ir raksturīgas daudzas straujas klepus lēkmes, kam seko ķērkšana vai smacējošs klepus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="81"> |
|
<prop type="lengthRatio">1.013157894736842</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is caused by bacteria in the mouth, nose and throat of an infected person.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šo slimību izraisa baktērija inficētā cilvēka mutes dobumā, degunā un rīklē.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="82"> |
|
<prop type="lengthRatio">1.0121951219512195</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Garais klepus ir ļoti infekcioza bakteriāla slimība, kas skar plaušas un elpceļus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="83"> |
|
<prop type="lengthRatio">0.8074074074074075</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Initially, symptoms resemble those of a common cold (sneezing, runny nose, low-grade fever and a mild cough).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sākotnēji simptomi līdzinās parastas saaukstēšanās simptomiem (šķaudīšana, iesnas, nedaudz paaugstināta temperatūra un neliels klepus).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="84"> |
|
<prop type="lengthRatio">1.1923076923076923</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can pertussis be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā var novērst garo klepu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="85"> |
|
<prop type="lengthRatio">0.9714285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis in unvaccinated infants or infants whose mother was unvaccinated can be particularly severe.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Nevakcinētiem zīdaiņiem vai zīdaiņiem, kuru māte nav vakcinēta, var būt īpaši smagi garā klepus simptomi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="86"> |
|
<prop type="lengthRatio">0.7</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurām personām pastāv garā klepus risks?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="87"> |
|
<prop type="lengthRatio">1.2</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In young infants the typical 'whoop' may never develop, and the coughing fits may be followed by brief periods when breathing stops.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Maziem zīdaiņiem var nebūt tipiska smacējoša klepus, un viņiem starp klepus lēkmēm var īsi apstāties elpošana.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="88"> |
|
<prop type="lengthRatio">1.1857142857142857</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Garais klepus izplatās gaisa pilienu ceļā, kad inficētā persona klepo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="89"> |
|
<prop type="lengthRatio">1.206896551724138</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir garā klepus simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="90"> |
|
<prop type="lengthRatio">1.1428571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir garā klepus komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="91"> |
|
<prop type="lengthRatio">0.8571428571428571</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kas ir garais klepus?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="92"> |
|
<prop type="lengthRatio">0.9230769230769231</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is pertussis spread?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā garais klepus izplatās?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="93"> |
|
<prop type="lengthRatio">1.108695652173913</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These episodes frequently end with the expulsion of a thick, clear mucous, often followed by vomiting.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šo lēkmju rezultātā no plaušām bieži izdalās biezas, dzidras gļotas, kam bieži seko vemšana.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="94"> |
|
<prop type="lengthRatio">1.3461538461538463</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is also known as whooping cough.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>To arī dēvē par Petrussis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="95"> |
|
<prop type="lengthRatio">1.25</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is pertussis treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā ārstē garo klepu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="96"> |
|
<prop type="lengthRatio">1.0454545454545454</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Thousands of volunteers</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tūkstošiem brīvprātīgo</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="97"> |
|
<prop type="lengthRatio">0.9855072463768116</prop> |
|
<tuv xml:lang="en"> |
|
<seg>its ingredients, including its inactive ingredients or ‘excipients';</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>tās sastāvdaļas, tostarp tās neaktīvās sastāvdaļas jeb "palīgvielas";</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="98"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This programme has to follow the procedures and protocols set by the regulators:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šajā programmā ir jāievēro regulatīvo iestāžu noteiktās procedūras un protokoli:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="99"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>its purity;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>tās tīrību;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="100"> |
|
<prop type="lengthRatio">0.9523809523809523</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Is the vaccine safe?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vai vakcīna ir droša?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="101"> |
|
<prop type="lengthRatio">0.9468085106382979</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These include the European Medicines Agency and other regulators in the EU/EEA countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Regulatīvo iestāžu vidū ir Eiropas Zāļu aģentūra un citas regulatīvās iestādes ES/EEZ valstīs.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="102"> |
|
<prop type="lengthRatio">1.05</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Approval of vaccines in the European Union</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu apstiprināšana Eiropas Savienībā</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="103"> |
|
<prop type="lengthRatio">1.15</prop> |
|
<tuv xml:lang="en"> |
|
<seg>how it is manufactured.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>tās ražošanas veidu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="104"> |
|
<prop type="lengthRatio">0.9298245614035088</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This involves tests in the laboratory and in animals.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas ietver laboratorijas testus un testus ar dzīvniekiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="105"> |
|
<prop type="lengthRatio">1.0526315789473684</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas izgatavotājs testē vakcīnu trijos klīnisko pārbaužu posmos ar aizvien lielāku cilvēku skaitu katrā posmā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="106"> |
|
<prop type="lengthRatio">1.6590909090909092</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How are the immune systems of the participants responding to the vaccine?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā dalībnieku imūnsistēmas reaģē uz vakcīnu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="107"> |
|
<prop type="lengthRatio">0.8217821782178217</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is followed by a clinical testing programme in humans, which can take around ten years from initial concept to authorisation and must adhere to strict standards.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pēc tam tiek sagatavota programma klīniskajiem testiem ar cilvēkiem, kuras ieviešana var ilgt aptuveni 10 gadus no sākotnējās koncepcijas līdz atļaujas saņemšanai, un tajā ir jāievēro stingri standarti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="108"> |
|
<prop type="lengthRatio">1.1612903225806452</prop> |
|
<tuv xml:lang="en"> |
|
<seg>At the end of the testing programme, the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘marketing authorisation' application.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Testēšanas programmas beigās vakcīnas izgatavotājs iesniedz rezultātus zāļu regulatīvajām iestādēm Eiropā kā daļu no "reģistrācijas apliecības" pieteikuma.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="109"> |
|
<prop type="lengthRatio">1.1363636363636365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is the optimal dose?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kāda ir optimālā deva?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="110"> |
|
<prop type="lengthRatio">0.9451219512195121</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Regulatīvās iestādes var apstiprināt vakcīnu tikai tad, ja tās testu rezultātu zinātniskais novērtējums apliecina, ka vakcīnas ieguvumi pārsniedz tās radīto risku .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="111"> |
|
<prop type="lengthRatio">1.164179104477612</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tās arī var veikt testus, lai pārliecinātos, ka tirgū laistajām vakcīnu partijām ir paredzētā kvalitāte un tās ir pareizi izgatavotas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="112"> |
|
<prop type="lengthRatio">0.9230769230769231</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Testing includes checking the vaccine's quality:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Testu laikā cita starpā pārbauda vakcīnas kvalitāti:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="113"> |
|
<prop type="lengthRatio">1.0208333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the most common short-term side effects?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir visbiežākās īslaicīgās blakusparādības?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="114"> |
|
<prop type="lengthRatio">1.1779661016949152</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Zāļu regulatīvās iestādes veic pārbaudes, lai pārliecinātos, ka vakcīnas izgatavotāja sniegtā informācija ir uzticama.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="115"> |
|
<prop type="lengthRatio">1.0408163265306123</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pirms vakcīnu var apstiprināt ES, tās izgatavotājam jāveic stingras pārbaudes, un pēc tam regulatīvajām iestādēm jāsniedz zinātniskais novērtējums.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="116"> |
|
<prop type="lengthRatio">0.9016393442622951</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Then the vaccine developer tests the vaccine's effects.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pēc tam vakcīnas izgatavotājs pārbauda vakcīnas efektivitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="117"> |
|
<prop type="lengthRatio">1.027027027027027</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the most common side effects?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir visbiežākās blakusparādības?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="118"> |
|
<prop type="lengthRatio">1.2949640287769784</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The companies are required to conduct stringent testing, for which the acceptance criteria are pre-defined by the authorities, on each batch of vaccine released onto the EU market.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katrai ES tirgū laistajai vakcīnas partijai uzņēmumiem jāveic stingras pārbaudes, kuru apstiprināšanas kritērijus iepriekš nosaka iestādes.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="119"> |
|
<prop type="lengthRatio">1.6666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Read more About us .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lasīt vairāk</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="120"> |
|
<prop type="lengthRatio">1.0056497175141244</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It also provides an overview of the mechanisms in place in the European Union (EU) to ensure that available vaccines conform to the highest standards of safety and effectiveness.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā sniedz arī pārskatu par Eiropas Savienībā (ES) ieviestajiem mehānismiem, ar kuriem nodrošina, ka pieejamās vakcīnas atbilst augstākajiem drošuma un efektivitātes standartiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="121"> |
|
<prop type="lengthRatio">1.079646017699115</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood...</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katrs vīruss un baktērija izraisa unikālu imūnsistēmas reakciju, kurā iesaistīts specifisks šūnu kopums asinīs...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="122"> |
|
<prop type="lengthRatio">1.2098765432098766</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer...</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pirms vakcīnu var apstiprināt ES, tās izgatavotājam jāiziet stingras pārbaudes...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="123"> |
|
<prop type="lengthRatio">0.9586776859504132</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šīs tīmekļa vietnes galvenais mērķis ir sniegt precīzus, objektīvus un aktuālus pierādījumus par vakcīnām un vakcināciju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="124"> |
|
<prop type="lengthRatio">1.1428571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines protect people during different stages of life.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas aizsargā cilvēkus dažādos dzīves posmos.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="125"> |
|
<prop type="lengthRatio">0.9512195121951219</prop> |
|
<tuv xml:lang="en"> |
|
<seg>European Vaccination Information Portal</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Eiropas Vakcinācijas informācijas portāls</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="126"> |
|
<prop type="lengthRatio">1.3636363636363635</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are recommended for different age...</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas iesaka dažādām vecuma...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="127"> |
|
<prop type="lengthRatio">1.2077922077922079</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects individuals against diseases that could have serious consequences for...</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija aizsargā indivīdus pret slimībām, kas varētu nopietni ietekmēt...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="128"> |
|
<prop type="lengthRatio">0.9629629629629629</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In healthy individuals it is usually a mild disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Veseliem cilvēkiem slimība parasti noris vieglā formā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="129"> |
|
<prop type="lengthRatio">1.1333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When to vaccinate</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kad vakcinēties</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="130"> |
|
<prop type="lengthRatio">1.1573033707865168</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases...</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija aizsargā vakcinētās personas un apkārtējos, kuri ir uzņēmīgi pret slimībām...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="131"> |
|
<prop type="lengthRatio">1.2580645161290323</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccination for individuals</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācijas ieguvumi indivīdam</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="132"> |
|
<prop type="lengthRatio">1.5333333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Rubella (German measles) is a viral infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masaliņas ir vīrusa infekcija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="133"> |
|
<prop type="lengthRatio">1.2424242424242424</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccination for the community</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācijas ieguvumi sabiedrībai</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="134"> |
|
<prop type="lengthRatio">1.6666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Trusted sources</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masaliņas</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="135"> |
|
<prop type="lengthRatio">0.7980769230769231</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masalas ir ļoti lipīga vīrusu slimība, ar kuru var saslimt jebkurā vecumā un kura var plaši izplatīties.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="136"> |
|
<prop type="lengthRatio">0.5904255319148937</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This website does not contain any specific information on the ongoing development of vaccines against COVID-19.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā ir Eiropas Savienības iniciatīva, kura tika izstrādāta saskaņā ar Padomes Ieteikumu par pastiprinātu sadarbību, kas vērsta pret vakcīnnovēršamām slimībām (pieņemts 2018. gada decembrī).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="137"> |
|
<prop type="lengthRatio">1.2333333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When symptoms do occur, they include:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Simptomu gadījumā tie ir šādi:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="138"> |
|
<prop type="lengthRatio">1.064102564102564</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The first dose is given between 10 and 18 months of age in most European countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lielākajā daļā Eiropas valstu pirmo devu ievada vecumā no 10 līdz 18 mēnešiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="139"> |
|
<prop type="lengthRatio">0.9714285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine is safe and effective and has very few side effects.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>MMR vakcīna ir droša un efektīva, un tās blakusparādības ir nedaudzas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="140"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Two doses of the vaccine are needed for maximum protection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Maksimālai aizsardzībai ir vajadzīgas divas vakcīnas devas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="141"> |
|
<prop type="lengthRatio">1.2323232323232323</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The second dose can be given one month or more after the first dose, in accordance with the national vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Otro devu var ievadīt vienu mēnesi vai vēlāk pēc pirmās devas saskaņā ar valsts vakcinācijas plānu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="142"> |
|
<prop type="lengthRatio">0.5294117647058824</prop> |
|
<tuv xml:lang="en"> |
|
<seg>red rash;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>sarkani izsitumi;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="143"> |
|
<prop type="lengthRatio">1.013986013986014</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažiem vakcīnas saņēmējiem rodas neinfekciozi viegli masalām līdzīgi izsitumi, parasti 7-14 dienas pēc vakcinācijas, kas izzūd 1-3 dienu laikā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="144"> |
|
<prop type="lengthRatio">1.0222222222222221</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Rubella (German measles) is a viral infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masaliņas (vācu masalas) ir vīrusa infekcija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="145"> |
|
<prop type="lengthRatio">1.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Up to 50% of people infected with rubella do not experience symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Līdz 50 % ar masaliņām inficēto simptomus nenovēro.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="146"> |
|
<prop type="lengthRatio">1.02</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The only protection against rubella is vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vienīgā aizsardzība pret masaliņām ir vakcinācija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="147"> |
|
<prop type="lengthRatio">0.9918032786885246</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ikviens, kurš nav masaliņas pārslimojis vai kurš nav vakcinēts ar MMR vakcīnu, ir pakļauts riskam inficēties ar masaliņām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="148"> |
|
<prop type="lengthRatio">1.0546875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Women who plan to become pregnant should check their vaccination status, as they cannot be vaccinated against rubella during pregnancy.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sievietēm, kuras plāno būt stāvoklī, jāpārbauda vakcinācijas statuss, jo grūtniecības laikā viņas nevar vakcinēt pret masaliņām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="149"> |
|
<prop type="lengthRatio">0.875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>MMR (masalu, epidēmiskā parotīta un masaliņu) vakcīna ir kombinēta vakcīna, kas aizsargā pret masalām, epidēmisko parotītu un masaliņām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="150"> |
|
<prop type="lengthRatio">1.16</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can rubella be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā var novērst masaliņas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="151"> |
|
<prop type="lengthRatio">0.9891304347826086</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ir ziņots par vieglām reakcijām, piemēram, drudzi, apsārtumu vai pietūkumu injekcijas vietā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="152"> |
|
<prop type="lengthRatio">1.0952380952380953</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pain and inflammation of the joints in adults.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>locītavu sāpes un iekaisums pieaugušajiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="153"> |
|
<prop type="lengthRatio">0.8947368421052632</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, if a woman gets rubella during the first three months of pregnancy, it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome (CRS).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr, ja sieviete pirmajā grūtniecības trimestrī saslimst ar masaliņām, pastāv liela varbūtība, ka slimība izraisīs spontāno abortu vai arī mazulis piedzims ar iedzimtām anomālijām, ko dēvē par iedzimto masaliņu sindromu (CRS).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="154"> |
|
<prop type="lengthRatio">0.9024390243902439</prop> |
|
<tuv xml:lang="en"> |
|
<seg>CRS can lead to deafness, cataracts and learning disabilities in the baby.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>CRS var izraisīt bērnu kurlumu, kataraktu un intelektuālās attīstības traucējumus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="155"> |
|
<prop type="lengthRatio">0.5777777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurš ir pakļauts riskam saslimt ar masaliņām?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="156"> |
|
<prop type="lengthRatio">1.1875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir masaliņu komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="157"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is rubella spread?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā masaliņas izplatās?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="158"> |
|
<prop type="lengthRatio">1.0842105263157895</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The consequences for unvaccinated pregnant women that get rubella are particularly severe, due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sekas nevakcinētām grūtniecēm, kas saslimst ar masaliņām, ir īpaši smagas, jo pastāv iespēja, ka saslimšana ar slimību grūtniecības laikā var izraisīt spontāno abortu vai bērnu CRS sindromu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="159"> |
|
<prop type="lengthRatio">1.2560975609756098</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masaliņu vīruss izplatās gaisa pilienu ceļā, kad inficētā persona klepo un šķauda.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="160"> |
|
<prop type="lengthRatio">1.2692307692307692</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir masaliņu simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="161"> |
|
<prop type="lengthRatio">0.9411764705882353</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kas ir masaliņas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="162"> |
|
<prop type="lengthRatio">1.5121951219512195</prop> |
|
<tuv xml:lang="en"> |
|
<seg>swollen lymph glands around the ears and the back of the head;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>pietūkuši limfmezgli ap ausīm un pakausī;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="163"> |
|
<prop type="lengthRatio">1.2105263157894737</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is rubella treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā ārstē masaliņas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="164"> |
|
<prop type="lengthRatio">1.1</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It analyses many sources of data, including:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā analizē daudzus datu avotus, tostarp:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="165"> |
|
<prop type="lengthRatio">0.9111111111111111</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This ensures that any possible risks are detected and managed as soon as possible.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā tiek nodrošināts, ka pēc iespējas ātrāk tiek konstatēti un pārvaldīti iespējamie riski.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="166"> |
|
<prop type="lengthRatio">0.8108108108108109</prop> |
|
<tuv xml:lang="en"> |
|
<seg>reports from patients, parents and healthcare professionals;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>ziņojumus no pacientiem, viņu vecākiem un veselības aprūpes speciālistiem;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="167"> |
|
<prop type="lengthRatio">0.9402985074626866</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When needed, EMA and the other European regulators take action.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ja nepieciešams, EMA un citas Eiropas regulatīvās iestādes rīkojas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="168"> |
|
<prop type="lengthRatio">0.8666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>information shared by other regulators.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>citu regulatīvo iestāžu kopīgoto informāciju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="169"> |
|
<prop type="lengthRatio">0.8811188811188811</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, they can provide updated guidance to healthcare workers, or even restrict the use of a vaccine in certain groups.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, tās var sniegt atjauninātus norādījumus veselības aprūpes nozares darbiniekiem vai pat ierobežot vakcīnas lietošanu noteiktās grupās.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="170"> |
|
<prop type="lengthRatio">1.0694444444444444</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA checks new information on the safety of all vaccines available in Europe.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>EMA pārbauda jaunu informāciju par visu Eiropā pieejamo vakcīnu drošumu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="171"> |
|
<prop type="lengthRatio">1.2560975609756098</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The process of monitoring the safety and managing the risks of medicines is called ‘pharmacovigilance'.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Zāļu drošuma uzraudzības un risku pārvaldības procesu dēvē par "farmakovigilanci".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="172"> |
|
<prop type="lengthRatio">1.0853658536585367</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kad vakcīna ir apstiprināta lietošanai, ES/EEZ valstu iestādes un Eiropas Zāļu aģentūra (EMA) pastāvīgi uzrauga blakusparādības cilvēkiem, kuri ir saņēmuši vakcīnu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="173"> |
|
<prop type="lengthRatio">0.7878787878787878</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information, see:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāku informāciju skatiet šeit:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="174"> |
|
<prop type="lengthRatio">1.0198675496688743</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Patients, healthcare professionals and pharmaceutical companies should report all suspected side effects to their national medicines regulatory authority.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pacientiem, veselības aprūpes speciālistiem un farmācijas uzņēmumiem jāziņo par visām iespējamām blakusparādībām viņu valsts zāļu regulatīvajā iestādē.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="175"> |
|
<prop type="lengthRatio">0.896551724137931</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Monitoring vaccine safety and reporting side effects</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu drošuma uzraudzība un ziņošana par blakusparādībām</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="176"> |
|
<prop type="lengthRatio">1.1403508771929824</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This helps to rule out the possibility that it was a coincidence or that it was caused by factors unrelated to the vaccine itself.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas palīdz izslēgt iespēju, ka tā ir sagadīšanās vai ka blakusparādības izraisījuši ar vakcīnu nesaistīti faktori.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="177"> |
|
<prop type="lengthRatio">1.1587301587301588</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These could be due to an illness or anxiety over being given the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šie faktori var būt slimība vai satraukums par saņemto vakcīnu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="178"> |
|
<prop type="lengthRatio">1.0186915887850467</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA carefully assesses suspected side effects to determine if there is a causal link with the vaccine or not.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>EMA rūpīgi novērtē iespējamās blakusparādības, lai noteiktu, vai starp tām un vakcīnu pastāv cēloņsakarība.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="179"> |
|
<prop type="lengthRatio">1.0666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information on these reported suspected side effects is publicly available on the European database of suspected adverse drug reaction reports .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Informācija par šīm ziņotajām iespējamām blakusparādībām ir publiski pieejama iespējamo zāļu blakusparādību ziņojumu Eiropas datubāzē .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="180"> |
|
<prop type="lengthRatio">1.0053191489361701</prop> |
|
<tuv xml:lang="en"> |
|
<seg>More information on how to report suspected side effects can be found in the prescribing information or package leaflet or the European database of suspected adverse drug reaction reports .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāka informācija par to, kā ziņot par iespējamām blakusparādībām, ir pieejama zāļu izrakstīšanas informācijā, zāļu aprakstā vai iespējamo zāļu blakusparādību ziņojumu Eiropas datubāzē .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="181"> |
|
<prop type="lengthRatio">2.5</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Monitoring vaccine safety & reporting side effects</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>klīniskos pētījumus;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="182"> |
|
<prop type="lengthRatio">1.4705882352941178</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When to avoid vaccination</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kad nevakcinēties</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="183"> |
|
<prop type="lengthRatio">1.2962962962962963</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination schedules in the EU/EEA</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācijas grafiki ES/EEZ</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="184"> |
|
<prop type="lengthRatio">0.9488636363636364</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Immunocompromised patients also benefit from those around them being fully vaccinated (such as family members, caregivers), as then they are also indirectly protected.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Imūnkompromitēti pacienti arī gūst labumu no tā, ka apkārtējie cilvēki ir pilnībā vakcinēti (piemēram, ģimenes locekļi, aprūpētāji), jo tādējādi arī viņi ir netieši aizsargāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="185"> |
|
<prop type="lengthRatio">1.25</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some cases, the completion of the immunisations needed is recommended prior to the start of a treatment, as during the treatment the patient may be at higher risks of infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažos gadījumos nepieciešamo imunizāciju iesaka pabeigt pirms ārstēšanas sākuma, jo ārstēšanas laikā pacientam var būt lielāks infekcijas risks.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="186"> |
|
<prop type="lengthRatio">0.8604651162790697</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It usually occurs within minutes of exposure to the source of the allergy.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā parasti rodas pāris minūšu laikā pēc tam, kad cilvēks ir pakļauts alerģijas avotam.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="187"> |
|
<prop type="lengthRatio">0.946969696969697</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Every effort should be made to see that women receive all routinely recommended vaccines before they reach child-bearing age.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Jāpieliek visas pūles, lai nodrošinātu, ka sievietes saņem visas regulāri ieteiktās vakcīnas pirms reproduktīvā vecuma sasniegšanas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="188"> |
|
<prop type="lengthRatio">1.009090909090909</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There may be other contraindications for specific vaccines, which need discussing with the healthcare provider.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Specifiskām vakcīnām var būt arī citas kontrindikācijas, kuras ir jāapspriež ar veselības aprūpes speciālistu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="189"> |
|
<prop type="lengthRatio">0.9741379310344828</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anaphylaxis is a rare, rapid, extreme allergic reaction which can cause shock, swelling and difficulty breathing.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Anafilaksija ir reta, strauja un smaga alerģiska reakcija, kas var izraisīt šoku, pietūkumu un apgrūtinātu elpošanu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="190"> |
|
<prop type="lengthRatio">0.8466257668711656</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Women of childbearing age should discuss with their healthcare provider which vaccines are recommended before, during and after pregnancy.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sievietēm reproduktīvajā vecumā ir jākonsultējas ar veselības aprūpes speciālistu par to, kādas vakcīnas ir ieteicamas pirms un pēc grūtniecības, kā arī tās laikā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="191"> |
|
<prop type="lengthRatio">1.037313432835821</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine is contraindicated to those allergic to any of the vaccine active substances or ingredients as listed in the product information.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu kontrindicē cilvēkiem, kuriem ir alerģija pret kādu no vakcīnas aktīvajām vielām vai sastāvdaļām, kas norādītas zāļu aprakstā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="192"> |
|
<prop type="lengthRatio">0.8264705882352941</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Certain immune system disorders (e.g. congenital immune deficiencies), or medical treatments (e.g. chemotherapy, a bone marrow or other organ transplant, or high doses of steroids) are contraindications for some vaccines, such as measles, mumps, rubella, varicella or oral typhoid.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažām vakcīnām, piemēram, vakcīnām pret masalām, epidēmisko parotītu, masaliņām, vējbakām vai perorālajai vakcīnai pret tīfu, kontrindikācijas ir noteikti imūnsistēmas traucējumi (piem., iedzimti imūndeficīta traucējumi) vai ārstēšanas veidi (piem., ķīmijterapija, kaulu smadzeņu vai cita orgāna transplantācija vai augstas steroīdu devas).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="193"> |
|
<prop type="lengthRatio">0.7699115044247787</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccines are contraindicated during pregnancy, such as measles, mumps and rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažas vakcīnas kontrindicē grūtniecības laikā, piemēram, vakcīnas pret masalām, epidēmisko parotītu un masaliņām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="194"> |
|
<prop type="lengthRatio">0.8893805309734514</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Someone who experiences an anaphylactic or other serious allergic reaction following a certain vaccine should not be given that vaccine again, unless the vaccine is definitively ruled out as the cause.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēkam, kuram rodas anafilaktiska vai cita veida smaga alerģiska reakcija pēc noteiktas vakcīnas saņemšanas, nedrīkst sniegt atkārtotu vakcīnu, ja vien netiek konstatēts, ka vakcīna noteikti nav alerģiskās reakcijas cēlonis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="195"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A history of 'anaphylactic' or other serious allergic reaction after receiving a vaccine is a contraindication to further doses of that vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ja iepriekš pēc vakcīnas saņemšanas ir radusies anafilaktiska vai cita veida smaga alerģiska reakcija, turpmākas šīs vakcīnas devas kontrindicē.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="196"> |
|
<prop type="lengthRatio">1.8773584905660377</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it. Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pirms vakcīnas saņemšanas vienmēr ar veselības aprūpes speciālistu jāapspriež iespējamās kontrindikācijas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="197"> |
|
<prop type="lengthRatio">1.0147058823529411</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is offered to women in accordance with national recommendations.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šāda iespēja sievietēm tiek piedāvāta atbilstoši valstu ieteikumiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="198"> |
|
<prop type="lengthRatio">1.05</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is the most common sexually transmitted infection worldwide.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā ir visizplatītākā seksuāli transmisīvā infekcija pasaulē.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="199"> |
|
<prop type="lengthRatio">0.8913043478260869</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About 40 of them can infect the genitals.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Aptuveni 40 no tiem var inficēt dzimumorgānus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="200"> |
|
<prop type="lengthRatio">0.9545454545454546</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāka informācija pieejama ECDC tīmekļa vietnē: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="201"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Routine HPV vaccination usually takes place between 9 and 14 years of age, in accordance with the national vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Parasti HPV vakcināciju veic vecumā no 9 līdz 14 gadiem atbilstoši valsts vakcinācijas grafikam.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="202"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In most cases, an HPV infection disappears on its own without causing any obvious symptoms or problems.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vairumā gadījumu HPV infekcija pazūd pati no sevis, neradot acīmredzamus simptomus vai kādas problēmas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="203"> |
|
<prop type="lengthRatio">1.125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There are more than 100 types of HPV viruses.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pastāv vairāk nekā 100 HPV vīrusu veidu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="204"> |
|
<prop type="lengthRatio">0.9829059829059829</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, sometimes the HPV infection can persist and cause after some years some of the complications listed below.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr dažreiz HPV infekcija var saglabāties un pēc dažiem gadiem izraisīt kādas no turpmāk norādītajām komplikācijām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="205"> |
|
<prop type="lengthRatio">1.3492063492063493</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The use of condoms is not 100% effective in preventing the transmission of the virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Prezervatīvu lietošana nenodrošina 100 % aizsardzību no vīrusa.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="206"> |
|
<prop type="lengthRatio">0.9487179487179487</prop> |
|
<tuv xml:lang="en"> |
|
<seg>If HPV does not go away it may cause:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ja HPV infekcija neizzūd, tā var radīt:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="207"> |
|
<prop type="lengthRatio">1.1616161616161615</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There is no treatment for the virus itself, but the health problems caused by HPV can be treated in different ways.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pret pašu vīrusu ārstēšanas nav, taču dažādos veidos var ārstēt HPV izraisītās veselības problēmas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="208"> |
|
<prop type="lengthRatio">1.0740740740740742</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A healthcare provider should be consulted for advice on the specific treatment options.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Par konkrētām ārstēšanas iespējām jākonsultējas ar veselības aprūpes speciālistu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="209"> |
|
<prop type="lengthRatio">1.0597014925373134</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dzemdes kakla vēzis ir Eiropā otrs izplatītākais vēzis pēc krūts vēža un tas visvairāk skar sievietes vecumā no 15 līdz 44 gadiem (1).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="210"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Genital warts can be treated using medication or by surgery.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dzimumorgānu kārpas var ārstēt ar zālēm vai operācijas ceļā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="211"> |
|
<prop type="lengthRatio">0.8867924528301887</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Other HPV-related cancers are also more treatable when diagnosed and treated early, but there are no specific screening programmes for these.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Citus ar HPV saistīta vēža veidus arī ir vieglāk izārstēt, ja tos diagnosticē un ārstē agrīnā stadijā, taču šo veidu vēžiem nav specifisku skrīninga programmu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="212"> |
|
<prop type="lengthRatio">1.0169491525423728</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who is sexually active is at risk of contracting HPV.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Jebkurai seksuāli aktīvai personai ir risks saslimt ar HPV.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="213"> |
|
<prop type="lengthRatio">0.8553459119496856</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact with an infected person.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēka papilomas vīrusa (HPV) infekcija ir vīrusu infekcija, kas galvenokārt tiek pārnesta seksuāla kontakta ceļā, nonākot tiešā kontaktā ar inficēto personu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="214"> |
|
<prop type="lengthRatio">0.8559322033898306</prop> |
|
<tuv xml:lang="en"> |
|
<seg>At least 14 HPV types, classified as ‘high risk', can cause cancer, such as cervical cancer in women.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vismaz 14 HPV veidi, kas klasificēti kā augsta riska veidi, var izraisīt vēzi, piemēram, dzemdes kakla vēzi sievietēm.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="215"> |
|
<prop type="lengthRatio">0.9230769230769231</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination of girls and boys against HPV can prevent HPV infections and consequently HPV-related diseases in both sexes, including genital and anal warts, cervical cancer and other cancers caused by HPV.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinējot meitenes un zēnus pret HPV, var novērst HPV infekciju un līdz ar to ar HPV saistītas slimības abiem dzimumiem, tostarp dzimumorgānu un anālās atveres kārpas, dzemdes kakla vēzi un HPV izraisītu citu veidu vēzi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="216"> |
|
<prop type="lengthRatio">1.3246753246753247</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is because HPV can also occasionally infect surrounding skin that is not protected by the condom.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas ir tāpēc, ka HPV nereti var inficēt prezervatīva nenosegto apkārtējo ādu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="217"> |
|
<prop type="lengthRatio">0.865979381443299</prop> |
|
<tuv xml:lang="en"> |
|
<seg>HPV is transmitted by direct contact, mainly sexual, with someone who has the virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>HPV izplatās tieša kontakta ceļā, galvenokārt seksuāla kontakta ceļā ar personu, kurai ir vīruss.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="218"> |
|
<prop type="lengthRatio">0.5945945945945946</prop> |
|
<tuv xml:lang="en"> |
|
<seg>genital and anal warts</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>dzimumorgānu un anālās atveres kārpas</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="219"> |
|
<prop type="lengthRatio">0.7837837837837838</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The 'low risk' HPV types can cause genital and anal warts.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>"Zema riska" HPV veidi var izraisīt dzimumorgānu un anālās atveres kārpas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="220"> |
|
<prop type="lengthRatio">0.9607843137254902</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Cervical cancer and tissue in the cervix that is described as ‘precancerous' can be identified early through cervical cancer screening and treated.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dzemdes kakla vēzi un dzemdes kaklā esošos audus, ko dēvē par "pirmsvēža veidojumiem", var agrīni identificēt, veicot dzemdes kakla skrīningu, un ārstēt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="221"> |
|
<prop type="lengthRatio">1.3157894736842106</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can HPV be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā var novērst HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="222"> |
|
<prop type="lengthRatio">0.8951048951048951</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The ‘high risk' HPV types can also cause anal and genital cancers, and some cancers of the head and neck, in both men and women.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>"Augsta riska" HPV veidi var izraisīt arī tūpļa vēzi un dzimumorgānu vēzi, ka arī dažu veidu galvas un kakla vēzi gan sievietēm, gan vīriešiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="223"> |
|
<prop type="lengthRatio">0.9911504424778761</prop> |
|
<tuv xml:lang="en"> |
|
<seg>cervical or other types of cancer (e.g. vulvar, vaginal, anal penile, and some cancers of the head and the neck)</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>dzemdes kakla un citu veidu vēzi (piem., vulvas, maksts un dzimumlocekļa vēzi un dažu veidu galvas un kakla vēzi)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="224"> |
|
<prop type="lengthRatio">1.0909090909090908</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kas ir HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="225"> |
|
<prop type="lengthRatio">1.2592592592592593</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir HPV komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="226"> |
|
<prop type="lengthRatio">1.380952380952381</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir HPV simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="227"> |
|
<prop type="lengthRatio">0.6875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurām personām pastāv HPV risks?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="228"> |
|
<prop type="lengthRatio">1.4615384615384615</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is HPV treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā ārstē HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="229"> |
|
<prop type="lengthRatio">0.8636363636363636</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact...</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēka papilomas vīrusa (HPV) infekcija ir vīrusu infekcija, kas galvenokārt tiek pārnesta seksuāla kontakta ceļā, nonākot tiešā...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="230"> |
|
<prop type="lengthRatio">1.170731707317073</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Influenza (flu) is a contagious respiratory illness caused by infection with an influenza virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Garais klepus ir ļoti infekcioza bakteriāla slimība, kas skar plaušas un elpceļus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="231"> |
|
<prop type="lengthRatio">0.5714285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About us</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lelādēt vairāk</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="232"> |
|
<prop type="lengthRatio">1.1150442477876106</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, to ensure community immunity against measles, public health authorities recommend that 95% of the population are vaccinated with two doses of the vaccine against measles (the MMR vaccine, which protects against measles, mumps and rubella).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, lai nodrošinātu kolektīvo imunitāti pret masalām, sabiedrības veselības iestādes iesaka vakcinēt 95 % iedzīvotāju grupas locekļu ar divām devām vakcīnas (MMR vakcīna, kas aizsargā pret masalām, cūciņām un masaliņām).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="233"> |
|
<prop type="lengthRatio">0.9620689655172414</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Furthermore, immunisation programmes help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Turklāt imunizācijas programmas palīdz mazināt sociālo, psiholoģisko un finansiālo slogu, ko slimības rada cilvēkiem un valdībām, mazinot spiedienu uz veselības aprūpes un sociālās aprūpes sistēmām un ļaujot cilvēkiem īstenot produktīvas darbības, tostarp izglītības un nodarbinātības jomā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="234"> |
|
<prop type="lengthRatio">0.8372093023255814</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination is the only way to ensure direct protection against tetanus.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija ir vienīgais veids, kā nodrošināt tiešu aizsardzību pret stingumkrampjiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="235"> |
|
<prop type="lengthRatio">1.074235807860262</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases, reducing the risk of diseases spreading among family members, school mates or colleagues, friends, neighbours and other people in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija aizsargā vakcinētās personas un apkārtējos, kuri ir uzņēmīgi pret slimībām, mazinot slimību izplatīšanās risku starp ģimenes locekļiem, skolasbiedriem vai kolēģiem, draugiem, kaimiņiem un citiem sabiedrības locekļiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="236"> |
|
<prop type="lengthRatio">0.9276595744680851</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It means that people who cannot be vaccinated, for instance because they are too young or allergic to vaccine components, benefit from others being vaccinated, because the disease cannot easily spread in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas nozīmē, ka cilvēki, kuri nevar saņemt vakcināciju, jo, piemēram, viņi ir pārāk jauni vai viņiem ir alerģija pret vakcīnas sastāvdaļām, gūst labumu no vakcinētajiem cilvēkiem, jo slimība starp cilvēkiem nevar tik viegli izplatīties.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="237"> |
|
<prop type="lengthRatio">0.9151515151515152</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These include babies, children, the elderly, people with weak immune systems, cancer patients, and people who cannot be vaccinated for medical reasons.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas ietver zīdaiņus, bērnus, gados vecākus cilvēkus, cilvēkus ar vāju imūnsistēmu, vēža pacientus un cilvēkus, kuri medicīnisku iemeslu dēļ nevar saņemt vakcināciju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="238"> |
|
<prop type="lengthRatio">1.0263157894736843</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In this way, vaccines indirectly protect others who are vulnerable to disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tādējādi vakcīnas netieši aizsargā arī citus, kuri ir uzņēmīgi pret slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="239"> |
|
<prop type="lengthRatio">0.91</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, tetanus can be encountered due to common injuries, including dog or cat bites.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, stingumkrampji var rasties ikdienišķu ievainojumu ceļā, tostarp no suņu vai kaķu kodumiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="240"> |
|
<prop type="lengthRatio">1.0075757575757576</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When enough people in a population are immune to an infectious disease, the disease is then unlikely to spread from person to person.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ja pietiekami daudz cilvēku iedzīvotāju grupā ir imūni pret infekcijas slimību, tā, visticamāk, neizplatīsies no cilvēka uz cilvēku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="241"> |
|
<prop type="lengthRatio">0.9696969696969697</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kolektīvā imunitāte rodas, kad pietiekami daudz iedzīvotāju grupā ir imūni pret infekcijas slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="242"> |
|
<prop type="lengthRatio">0.8586956521739131</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, people cannot rely on community immunity for some infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr attiecībā uz dažām infekcijas slimībām cilvēki nevar paļauties uz kolektīvo imunitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="243"> |
|
<prop type="lengthRatio">1.3043478260869565</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Situation of measles in the EU</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Situācija ar masalām ES</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="244"> |
|
<prop type="lengthRatio">0.9339622641509434</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It provides options for the user to filter information by criteria such as disease and time-period.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tajā ir paredzētas iespējas lietotājam filtrēt informāciju pēc tādiem kritērijiem kā slimība un laikposms.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="245"> |
|
<prop type="lengthRatio">0.943089430894309</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The data is based on information submitted and verified by Member States through ECDC's disease surveillance system.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dati ir balstīti uz informāciju, ko dalībvalstis iesniegušas un pārbaudījušas, izmantojot ECDC slimību uzraudzības sistēmu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="246"> |
|
<prop type="lengthRatio">0.9863013698630136</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Below are the most recent data on measles outbreaks in EU Member States.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Zemāk ir sniegti jaunākie dati par masalu uzliesmojumiem ES dalībvalstīs.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="247"> |
|
<prop type="lengthRatio">1.1185185185185185</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Infekcijas slimību uzraudzības atlantā sniegti dati par citām vakcīnregulējamām slimībām, piemēram, difteriju, garo klepu un masaliņām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="248"> |
|
<prop type="lengthRatio">1.1666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These include:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tie ir šādi:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="249"> |
|
<prop type="lengthRatio">0.96</prop> |
|
<tuv xml:lang="en"> |
|
<seg>An example is aluminium;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemērs tam ir alumīnijs;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="250"> |
|
<prop type="lengthRatio">1.0694444444444444</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition to one or more antigens, there are other components in a vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Papildus vienam vai vairākiem antigēniem vakcīnā ir arī citi komponenti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="251"> |
|
<prop type="lengthRatio">1.3956043956043955</prop> |
|
<tuv xml:lang="en"> |
|
<seg>adjuvants: these improve the immune response to the vaccine by making the response stronger, faster and more sustained in time.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>adjuvanti: tie uzlabo imūnreakciju uz vakcīnu, padarot reakciju stiprāku, ātrāku un ilgāku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="252"> |
|
<prop type="lengthRatio">0.9827586206896551</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These substances are consistently controlled to ensure they are present at levels that have been shown to be safe.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šīs vielas tiek regulāri kontrolētas, lai nodrošinātu, ka tās vakcīnā ir tādā līmenī, kāds tiek uzskatīts par drošu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="253"> |
|
<prop type="lengthRatio">0.9433962264150944</prop> |
|
<tuv xml:lang="en"> |
|
<seg>excipients: these are inactive ingredients, like water, or sodium chloride (salt), as well as the preservatives or stabilisers that help the vaccine remain unchanged during storage, keeping it active.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>palīgvielas: tās ir aktīvas sastāvdaļas, piemēram, ūdens vai nātrija hlorīds (sāls), kā arī konservanti vai stabilizētāji, kas palīdz nodrošināt vakcīnas nemainīgumu uzglabāšanas laikā, saglabājot tās aktivitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="254"> |
|
<prop type="lengthRatio">1.1861702127659575</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Whenever these substances are present at a level that might trigger a reaction in a sensitive or allergic individual, their presence is declared in the information provided to healthcare workers and patients on the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kad šo vielu daudzums vakcīnā ir tādā līmenī, kas jutīgiem vai alerģiskiem cilvēkiem varētu izraisīt reakciju, to klātbūtni norāda informācijā veselības aprūpes darbiniekiem un pacientiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="255"> |
|
<prop type="lengthRatio">0.8786610878661087</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, the package leaflet will state if there are special precautions for use of a vaccine in people with certain allergies, such as vaccines including trace amounts of egg in people with an egg allergy.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, lietošanas instrukcijā būs norādīts, ja cilvēkiem ar noteiktām alerģijām vakcīnas saņemšanas laikā ir jāievēro īpaša piesardzība, piemēram, saņemot vakcīnas, kurās ir izsekojams neliels olu saturs cilvēkiem ar alerģiju pret olām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="256"> |
|
<prop type="lengthRatio">1.0192307692307692</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There may also be trace amounts of other substances used in the manufacturing process, such as ovalbumin (a protein found in eggs) or neomycin (an antibiotic).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnās var būt arī neliels daudzums citu vielu, ko izmanto ražošanas procesā, piemēram, ovalbumīns (olās esoša olbaltumviela) vai neomicīns (antibiotika).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="257"> |
|
<prop type="lengthRatio">0.7711864406779662</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Regulators check that their benefits are weighed against the risk of any reactions to them.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Regulatīvās iestādes nodrošina, ka tiek pienācīgi novērtēta šo vakcīnu izraisīto reakciju ieguvumu un risku attiecība.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="258"> |
|
<prop type="lengthRatio">1.186206896551724</prop> |
|
<tuv xml:lang="en"> |
|
<seg>If a person does not know if they have been vaccinated against a certain disease they can usually get an extra dose without increasing the risk of serious side effects (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ja persona nezina, vai tā ir vakcinēta pret noteiktu slimību, tā parasti var saņemt papildu devu, nepalielinot nopietnu blakusparādību risku (1).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="259"> |
|
<prop type="lengthRatio">0.7547169811320755</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most vaccines provide lifelong immunity.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lielākā daļa vakcīnu nodrošina imunitāti mūža garumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="260"> |
|
<prop type="lengthRatio">1.0113636363636365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some people may have missed a vaccination or did not get the recommended number of doses.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Daži cilvēki, iespējams, nav veikuši vakcināciju vai nav saņēmuši ieteicamo devu skaitu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="261"> |
|
<prop type="lengthRatio">1.08300395256917</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, pieaugot pusaudžu un gados jaunu pieaugušo saslimstībai ar masalām, vairākās ES/EEZ valstīs ir programmas, kas paredzētas cilvēkiem, kuri, iespējams, nav vakcinēti pret masalām, kad bija jaunāki, vai ir pārāk veci, lai to saņemtu bērnu vecumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="262"> |
|
<prop type="lengthRatio">0.8</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They can still catch up.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Viņi joprojām var vakcinēties.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="263"> |
|
<prop type="lengthRatio">0.9207920792079208</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, some vaccines provide immunity that decreases over time, known as ‘waning immunity'.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Taču dažas vakcīnas nodrošina imunitāti, kas samazinās laika gaitā, ko dēvē par "sarūkošu imunitāti".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="264"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Everyone should check if they have had the nationally recommended vaccinations, and consult a medical professional in case any catch-ups are needed.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ikvienam būtu jāpārbauda, vai viņam ir veikta valsts ieteiktā vakcinācija, un jākonsultējas ar ārstu par jautājumu, vai ir nepieciešama vakcinācija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="265"> |
|
<prop type="lengthRatio">0.8255813953488372</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Catch-up vaccination programmes for specific diseases may be organised.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Attiecībā uz noteiktām slimībām var būt organizētas nokavētas vakcinācijas programmas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="266"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This may involve looking at vaccination records or the vaccination schedules in place when the person was born.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>To var izdarīt, apskatot vakcinācijas ierakstus vai vakcinācijas grafikus, ko piemēro personas dzimšanas brīdī.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="267"> |
|
<prop type="lengthRatio">0.8716216216216216</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For some diseases, such as varicella (chickenpox) and rubella, it is also possible to do a test to check if the person is immune.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Attiecībā uz dažām slimībām, piemēram, vējbakām un masaliņām, ir iespējams veikt arī testu, lai pārbaudītu, vai personai ir izveidojusies imunitāte.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="268"> |
|
<prop type="lengthRatio">0.825</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Catch-up vaccination and boosters</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Nokavēta vakcinācija un atkārtotas devas</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="269"> |
|
<prop type="lengthRatio">1.0674846625766872</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažās valstīs iesaka ievadīt atkārtotas devas ar regulāriem intervāliem pusaudžiem un pieaugušajiem, lai uzturētu imunitāti ilgākā laika posmā pret šādām slimībām:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="270"> |
|
<prop type="lengthRatio">0.9861111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They just take into account different circumstances and health systems.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tajos ir ņemti vērā tikai dažādi apstākļi un veselības aprūpes sistēmas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="271"> |
|
<prop type="lengthRatio">1.1518987341772151</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The differences between vaccination schedules do not mean that some are better than others.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Atšķirības starp vakcinācijas grafikiem nenozīmē, ka daži ir labāki par citiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="272"> |
|
<prop type="lengthRatio">1.0824742268041236</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines in the national schedules are given in the appropriate timeframes to ensure adequate protection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas valstu grafikos ir norādītas piemērotos termiņos, lai nodrošinātu pienācīgu aizsardzību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="273"> |
|
<prop type="lengthRatio">1.1875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pastāv dažas atšķirības, kā valstis organizē to vakcinācijas grafikus, kas ir līdzīgi, bet nav identiski dažādās ES/EEZ valstīs.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="274"> |
|
<prop type="lengthRatio">1.145922746781116</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Factors driving such differences may include the disease's burden, prevalence of the disease and trends in different countries, the resources and structures of healthcare systems, political and cultural factors, as well as the resilience of the vaccination programme.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Faktori, kas veicina šādas atšķirības, var būt slimības slogs, slimības izplatība un tendences dažādās valstīs, veselības aprūpes sistēmu resursi un struktūras, politiskie un kultūras faktori, kā arī vakcinācijas programmas noturība.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="275"> |
|
<prop type="lengthRatio">1.0136054421768708</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each EU/EEA country is responsible for its own national public health policy, including its national immunisation programme and vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katra ES/EEZ valsts ir atbildīga par savu valsts sabiedrības veselības politiku, tostarp par valsts imunizācijas programmu un vakcinācijas grafiku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="276"> |
|
<prop type="lengthRatio">0.9402985074626866</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The same level of protection is ensured in each EU/EEA country.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Visās ES/EEZ valstīs tiek nodrošināts vienāds aizsardzības līmenis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="277"> |
|
<prop type="lengthRatio">0.9932659932659933</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These may include the age and population to be vaccinated (for example, all children of a certain age or only those in a risk group), the exact type of vaccine (e.g. some ingredients may differ), the number and timing of doses, and whether a vaccine is given alone or in combination with others.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas var būt atšķirīgs vakcinācijas vecums un iedzīvotāju grupa (piemēram, visi noteikta vecuma bērni vai tikai riska grupas bērni), noteikts vakcīnas veids (piemēram, dažas vakcīnu sastāvdaļas var atšķirties), devu skaits un grafiks, kā arī vai vakcīnu ievada atsevišķi vai kopā ar citām vakcīnām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="278"> |
|
<prop type="lengthRatio">1.2777777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The childhood vaccination schedules in all EU/EEA countries include the vaccination against:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Bērnu vakcinācijas grafiki visās ES/EEZ valstīs ietver vakcināciju pret:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="279"> |
|
<prop type="lengthRatio">1.6521739130434783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information on the national vaccination schedules in EU/EEA countries can be found in the ECDC Vaccine Scheduler .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Informācija par valsts vakcinācijas grafikiem ES/EEZ ir pieejama ECDC</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="280"> |
|
<prop type="lengthRatio">4.428571428571429</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>masalām</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="281"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>the eyes become red and sensitive to light;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>acis kļūst sarkanas un jutīgas pret gaismu;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="282"> |
|
<prop type="lengthRatio">1.1166666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>on the third to seventh day, the temperature may reach up to 41 ⁰C;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>trešajā līdz septītajā dienā temperatūra var sasniegt 41 °C;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="283"> |
|
<prop type="lengthRatio">0.8909090909090909</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/measles/facts/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāka informācija pieejama ECDC tīmekļa vietnē: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="284"> |
|
<prop type="lengthRatio">1.044776119402985</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is a serious disease that can lead to complications and even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā ir nopietna slimība, kas var izraisīt komplikācijas un pat nāvi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="285"> |
|
<prop type="lengthRatio">0.9375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>30% of children and adults infected with measles can develop complications.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>30 % bērnu un pieaugušo, kuri ir inficēti ar masalām, var rasties komplikācijas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="286"> |
|
<prop type="lengthRatio">1.2771084337349397</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šīs faktu lapas informācija ir paredzēta vispārīgas informēšanas nolūkos, un ar to nedrīkst aizstāt veselības aprūpes speciālista individuālu ekspertīzi un spriedumu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="287"> |
|
<prop type="lengthRatio">0.8796296296296297</prop> |
|
<tuv xml:lang="en"> |
|
<seg>a red rash lasting four to seven days begins on the face and then spreads over the entire body;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>sarkani izsitumi, kas ilgst četras līdz septiņas dienas, sākas uz sejas un pēc tam izplatās pa visu ķermeni;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="288"> |
|
<prop type="lengthRatio">1.118279569892473</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is estimated that one person with measles can infect on average between 12 and 18 unprotected people.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tiek lēsts, ka viens cilvēks ar masalām var inficēt vidēji 12 līdz 18 neaizsargātus cilvēkus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="289"> |
|
<prop type="lengthRatio">0.8225806451612904</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The only protection against measles is vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vienīgais veids, kā aizsargāties pret masalām, ir vakcinācija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="290"> |
|
<prop type="lengthRatio">1.21875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The first dose is given between 10 and 18 months of age in European countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Eiropas valstīs pirmo devu ievada vecumā no 10 līdz 18 mēnešiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="291"> |
|
<prop type="lengthRatio">1.1020408163265305</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles spreads easily among unvaccinated individuals.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masalas viegli izplatās nevakcinētu cilvēku vidū.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="292"> |
|
<prop type="lengthRatio">0.8582089552238806</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Symptoms include personality changes, gradual mental deterioration, muscle spasms and other neuromuscular symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Simptomi ietver izmaiņas personībā, pakāpenisku garīgās veselības pasliktināšanos, muskuļu spazmas un citus neiromuskulāros simptomus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="293"> |
|
<prop type="lengthRatio">1.0576923076923077</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There is no cure for SSPE and it always leads to death.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>SSPE nevar izārstēt, un tas vienmēr beidzas ar nāvi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="294"> |
|
<prop type="lengthRatio">1.0188679245283019</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Such dose before the age of nine months is supplementary to the two doses included in the national vaccination programme, which are aimed to give full protection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šāda deva pirms deviņu mēnešu vecuma sasniegšanas papildina valsts vakcinācijas programmā iekļautās divas devas, kuru mērķis ir nodrošināt pilnīgu aizsardzību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="295"> |
|
<prop type="lengthRatio">1.0872093023255813</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Infants from six to nine months of age who are in an area - or will be travelling to areas - with high risk of exposure to measles, should receive a supplementary dose of the MMR vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Zīdaiņiem vecumā no sešiem līdz deviņiem mēnešiem, kuri atrodas vai dosies uz apgabaliem, kuros ir augsts masalu saslimstības risks, būtu jāsaņem MMR vakcīnas papildu deva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="296"> |
|
<prop type="lengthRatio">1.0666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Virus-containing droplets can remain in the air for several hours and the virus remains infectious on contaminated surfaces for up to two hours.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vīrusu saturoši pilieni var palikt gaisā vairākas stundas, un vīruss uz piesārņotajām virsmām saglabājas infekciozs līdz divām stundām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="297"> |
|
<prop type="lengthRatio">0.9393939393939394</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles symptoms usually appear after 10-12 days of infection:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masalu simptomi parasti parādās 10 līdz 12 dienas pēc inficēšanās:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="298"> |
|
<prop type="lengthRatio">0.9925373134328358</prop> |
|
<tuv xml:lang="en"> |
|
<seg>SSPE typically appears several years after the affected patient had measles; on average it is seen 7 to 10 years after the infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>SSPE parasti parādās vairākus gadus pēc tam, kad slimajam pacientam bijušas masalas; vidēji to novēro 7 līdz 10 gadus pēc inficēšanās.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="299"> |
|
<prop type="lengthRatio">1.0263157894736843</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antibiotics are not effective against measles because it is caused by a virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Antibiotikas nav iedarbīgas pret masalām, jo slimības izraisītājs ir vīruss.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="300"> |
|
<prop type="lengthRatio">0.8602620087336245</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lai izvairītos no masalu tālākas izplatīšanās, tiek veikti dažādi pasākumi, piemēram, karantīna no skolas vai darba gan slimajai personai, gan ciešā saskarē ar saslimušo esošajām personām, kurām ir neskaidrs vakcinācijas statuss.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="301"> |
|
<prop type="lengthRatio">1.125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ikviens, kurš nav vakcinēts pret masalām vai nav tās pārslimojis, var saslimt ar masalām jebkurā vecumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="302"> |
|
<prop type="lengthRatio">0.9897959183673469</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pneumonia is a potential serious complication that has led to the death of some measles patients.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plaušu karsonis ir potenciāla nopietna komplikācija, kas ir izraisījusi dažu masalu pacientu nāvi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="303"> |
|
<prop type="lengthRatio">0.92</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is measles treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā masalas tiek ārstētas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="304"> |
|
<prop type="lengthRatio">0.8450704225352113</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pneumonia is the most common cause of measles-related death.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plaušu karsonis ir visizplatītākais ar masalām saistītas nāves cēlonis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="305"> |
|
<prop type="lengthRatio">1.0597014925373134</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A person who is infected may transmit measles even before the rash appears (usually 4 days), and for about 4 days after the rash has appeared.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Inficēta persona var pārnēsāt masalas pat pirms izsitumu parādīšanās (parasti 4 dienas) un aptuveni 4 dienas pēc izsitumu parādīšanās.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="306"> |
|
<prop type="lengthRatio">0.8387096774193549</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurš ir pakļauts masalu riskam?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="307"> |
|
<prop type="lengthRatio">1.0689655172413792</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine may be given earlier in life during outbreaks.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>MMR vakcīnu slimības uzliesmojumu laikā var ievadīt agrāk.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="308"> |
|
<prop type="lengthRatio">0.9174311926605505</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most people recover with supportive treatment, which can include hydration and anti-fever medicines.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lielākā daļa cilvēku atlabst ar atbalstošu ārstēšanu, kas var ietvert šķidruma uzņemšanu un pretdrudža zāles.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="309"> |
|
<prop type="lengthRatio">1.125748502994012</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Apmēram 1 no 1 000 masalu slimniekiem rodas smadzeņu audu iekaisums (encefalīts), kas izraisa pastāvīgu neiroloģisko invaliditāti aptuveni vienā no četriem gadījumiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="310"> |
|
<prop type="lengthRatio">1.0288461538461537</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masalas ir ļoti lipīga vīrusu slimība, ar kuru var saslimt jebkurā vecumā un kura var plaši izplatīties.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="311"> |
|
<prop type="lengthRatio">1.4333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There is no specific treatment for measles.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masalām nav īpašas ārstēšanas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="312"> |
|
<prop type="lengthRatio">1.0200803212851406</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Very rarely, a persistent measles virus infection can produce subacute sclerosing panencephalitis (SSPE), a disease in which nerves and brain tissue degenerate progressively and which is more likely to appear if measles infection occurs at a younger age.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ļoti retos gadījumos noturīga masalu vīrusa infekcija var izraisīt subakūtu sklerozu panencefalītu (SSPE) - slimību, kurā nervu un smadzeņu audi pakāpeniski deģenerējas un kura visticamāk parādās, ja inficēšanās ar masalām ir notikusi agrīnā vecumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="313"> |
|
<prop type="lengthRatio">1.0063291139240507</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr antibiotikas bieži izmanto, lai ārstētu bakteriālu infekciju komplikācijas, kas var attīstīties masalu dēļ, piemēram, plaušu karsoni un ausu infekcijas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="314"> |
|
<prop type="lengthRatio">1.205128205128205</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These can include ear infections and diarrhoea.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tās var būt ausu infekcijas un caureja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="315"> |
|
<prop type="lengthRatio">0.9085365853658537</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7 - 14 days after vaccination, which disappears within 1 - 3 days.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažiem vakcīnu saņēmējiem rodas neinfekciozi mēreni masalām līdzīgi izsitumi, parasti 7 līdz 14 dienas pēc vakcinācijas, un kuri izzūd vienas līdz trīs dienu laikā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="316"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella (German measles).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>MMR (masalu, epidēmiskā parotīta un masaliņu) vakcīna ir kombinēta vakcīna, kas aizsargā pret masalām, epidēmisko parotītu un masaliņām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="317"> |
|
<prop type="lengthRatio">1.0416666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>small white spots may also appear on the gums and the inside of the cheeks.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>uz smaganām un vaigu iekšpusē var arī parādīties nelieli balti plankumi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="318"> |
|
<prop type="lengthRatio">1.0666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kas ir masalas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="319"> |
|
<prop type="lengthRatio">1.375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The mortality rate for measles is 1-3 persons per 1 000 cases and highest in those younger than five years of age and among immunocompromised individuals.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Augstākais mirstības rādītājs ir personām, kuras jaunākas par pieciem gadiem, kā arī imūnkompromitētām personām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="320"> |
|
<prop type="lengthRatio">0.974025974025974</prop> |
|
<tuv xml:lang="en"> |
|
<seg>initial symptoms resemble a cold with a runny nose, cough and a mild fever;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>sākotnējie simptomi atgādina saaukstēšanos ar iesnām, klepu un vieglu drudzi;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="321"> |
|
<prop type="lengthRatio">1.1</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is measles spread?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā masalas izplatās?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="322"> |
|
<prop type="lengthRatio">1.2875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The measles virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masalu vīruss izplatās gaisa pilienu ceļā, kad inficētā persona klepo un šķauda.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="323"> |
|
<prop type="lengthRatio">1.2666666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir masalu komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="324"> |
|
<prop type="lengthRatio">0.8529411764705882</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can measles be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā novērst inficēšanos ar masalām?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="325"> |
|
<prop type="lengthRatio">1.375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir masalu simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="326"> |
|
<prop type="lengthRatio">1.1584158415841583</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects individuals against diseases that could have serious consequences for their health, for example:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija aizsargā indivīdus pret slimībām, kuras varētu nopietni ietekmēt viņu veselību, piemēram:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="327"> |
|
<prop type="lengthRatio">1.0416666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This list with examples includes diseases for which vaccines are included in the national immunisation programmes, and/or are given to persons considered to be at a higher risk of getting the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šajā sarakstā ar piemēriem ir iekļautas slimības, kurām vakcīnas ir ietvertas valsts imunizācijas programmās un/vai tiek ievadītas cilvēkiem, kuri atrodas paaugstināta inficēšanās riska grupā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="328"> |
|
<prop type="lengthRatio">0.9477611940298507</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>garais klepus var būt sevišķi nopietna slimība zīdaiņiem, kuras dēļ rodas klepus lēkmes, kas var atkārtoties līdz pat diviem mēnešiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="329"> |
|
<prop type="lengthRatio">0.9622641509433962</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death (5).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Var būt arī tādas komplikācijas kā pneimonija, encefalopātija (smadzeņu slimība), lēkmes vai pat nāve (5).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="330"> |
|
<prop type="lengthRatio">0.8956521739130435</prop> |
|
<tuv xml:lang="en"> |
|
<seg>meningococcal disease kills 1 in 10 people affected, even with prompt diagnosis and treatment, while problems including neurological or hearing impairment and amputation occur in up to 20% of survivors (3);</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>meningokoku infekcijas slimības dēļ mirst 1 no 10 inficētajiem, neskatoties uz ātru diagnosticēšanu un ārstēšanu, savukārt līdz pat 20 % izdzīvojušo rodas neiroloģiskas problēmas, dzirdes traucējumi vai ir nepieciešama amputācija;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="331"> |
|
<prop type="lengthRatio">0.9128440366972477</prop> |
|
<tuv xml:lang="en"> |
|
<seg>almost 9 out of 10 babies born to mothers who had rubella in early pregnancy, will suffer from congenital rubella syndrome (with conditions such as deafness, cataracts and learning disabilities) (2);</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>gandrīz 9 no 10 zīdaiņiem, kuru mātes slimoja ar masaliņām agrīnā grūtniecības posmā, cietīs no iedzimtā masaliņu sindroma (no tādām slimībām kā, piemēram, kurlums, katarakta un intelektuālās attīstības traucējumi (2);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="332"> |
|
<prop type="lengthRatio">1.1022727272727273</prop> |
|
<tuv xml:lang="en"> |
|
<seg>measles is highly contagious and 3 out of 10 people affected develop complications (4), which can include ear infection, diarrhoea, pneumonia and encephalitis (inflammation of the brain tissue);</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>masalas ir ļoti infekcioza slimība un 3 no 10 inficētajiem rodas komplikācijas (4), kas var ietvert auss iekaisumu, caureju, pneimoniju un encefalītu (smadzeņu audu iekaisumu);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="333"> |
|
<prop type="lengthRatio">1.0277777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>diphtheria kills 1 in every 10 people who get it, even with treatment (1);</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>difterijas dēļ mirst 1 no 10 inficētajiem, neskatoties uz ārstēšanu (1);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="334"> |
|
<prop type="lengthRatio">0.6461538461538462</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(4) US CDC Pink Book - Measles: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>(4) ASV Slimību kontroles un profilakses centra (CDC) rozā grāmata - masalas: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="335"> |
|
<prop type="lengthRatio">0.9390243902439024</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(5) ECDC factsheet - Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>(5) ECDC faktu lapa - garais klepus: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="336"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(2) ECDC factsheet - Congenital Rubella Syndrome: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>(2) ECDC faktu lapa - iedzimto masaliņu sindroms: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="337"> |
|
<prop type="lengthRatio">0.9130434782608695</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(3) ECDC factsheet - Meningococcal disease: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>(3) ECDC faktu lapa - meningokoku infekcijas slimība: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="338"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Decisions on vaccines in use in different European countries</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lēmumi par lietošanā esošām vakcīnām dažādās Eiropas valstīs</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="339"> |
|
<prop type="lengthRatio">0.9122807017543859</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Combined use of vaccines is well established and based on scientific studies on its benefits and safety.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu kombinēta saņemšana ir vispārpieņemta un balstīta uz zinātniskiem pētījumiem par to ieguvumiem un drošumu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="340"> |
|
<prop type="lengthRatio">0.9423076923076923</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is based on local conditions, such as how common the disease is, as well as economic factors.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lēmuma pamatā ir vietējie apstākļi, piemēram, slimības sastopamības biežums, kā arī ekonomiskie faktori.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="341"> |
|
<prop type="lengthRatio">1.014218009478673</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition, vaccines to protect against specific diseases are sometimes recommended for ‘high-risk' groups, such as people with long-term health conditions or people planning to travel to other parts of the world.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Papildus tam vakcīnas, kas aizsargā pret noteiktām slimībām, reizēm iesaka augsta riska grupām, piemēram, cilvēkiem ar hroniskiem veselības traucējumiem vai cilvēkiem, kuri plāno ceļot uz citām pasaules valstīm.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="342"> |
|
<prop type="lengthRatio">1.0432098765432098</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information about national vaccination programmes, see the ECDC vaccine scheduler and visit the official websites on immunisation of the EU/EEA countries here .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāku informāciju par valsts vakcinācijas programmām skatiet ECDC vakcīnu grafikā un apmeklējiet oficiālās tīmekļa vietnes par imunizāciju ES/EEZ valstīs šeit .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="343"> |
|
<prop type="lengthRatio">0.9559748427672956</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Individual European countries decide which vaccines should be part of their national vaccination programmes and funded by their national health systems.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katra Eiropas valsts individuāli nolemj, kuras vakcīnas tiks iekļautas to valsts vakcinācijas programmās un būs to valsts veselības aprūpes sistēmu apmaksātas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="344"> |
|
<prop type="lengthRatio">1.1416666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lielākā daļa vakcinācijas programmu ES/EEZ ietver vakcīnas līdz pat 20 slimībām, un cilvēki tās saņem konkrētos vecumos.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="345"> |
|
<prop type="lengthRatio">1.0987654320987654</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccines protect against only one disease, but others protect against more than one.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažas vakcīnas aizsargā tikai pret vienu slimību, savukārt citas - pret vairākām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="346"> |
|
<prop type="lengthRatio">1.0978260869565217</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Sometimes, more than one vaccine may be given at once to protect against several infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Reizēm var būt jāsaņem vairākas vakcīnas, lai aizsargātos pret vairākām infekcijas slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="347"> |
|
<prop type="lengthRatio">0.8148148148148148</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It can spread quickly.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā var strauji izplatīties.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="348"> |
|
<prop type="lengthRatio">1.1515151515151516</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine is safe and effective.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>MMR vakcīna ir droša un efektīva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="349"> |
|
<prop type="lengthRatio">1.0606060606060606</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are used in hundreds of millions of people worldwide each year to protect from serious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas saņem simtiem miljonu cilvēku katru gadu visā pasaulē, lai aizsargātos no smagām slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="350"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles had almost been eliminated in many European countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Daudzās Eiropas valstīs masalas ir gandrīz pilnībā izskaustas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="351"> |
|
<prop type="lengthRatio">1.0422535211267605</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It will often lead to hospitalisation in infants, and the risk of complications and hospitalisation increases for infants younger than three months.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Zīdaiņiem bieži vien ir vajadzīga hospitalizācija, un komplikāciju un hospitalizācijas risks pieaug zīdaiņiem, kuri jaunāki par trim mēnešiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="352"> |
|
<prop type="lengthRatio">0.8690476190476191</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It can cause severe spasms of cough and usually lasts three to six weeks.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Slimība var izraisīt smagas klepus spazmas un parasti ilgst trīs līdz sešas nedēļas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="353"> |
|
<prop type="lengthRatio">1.1290322580645162</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About 20% of infants will have redness and pain at the injection site.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Aptuveni 20 % zīdaiņu būs apsārtums un sāpes injekcijas vietā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="354"> |
|
<prop type="lengthRatio">0.8787878787878788</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Less than 5% will have fever.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Mazāk nekā 5 % bērnu būs drudzis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="355"> |
|
<prop type="lengthRatio">1.1714285714285715</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, since October 2016 a resurgence of measles has been observed in the EU/EEA, with outbreaks in several countries (2), due to a decline in vaccination rates.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr kopš 2016. gada oktobra ir novēroti masalu gadījumi ES/EEZ un uzliesmojumi vairākās valstīs (2) vakcinēšanās skaita samazināšanās dēļ.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="356"> |
|
<prop type="lengthRatio">1.1506849315068493</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination against pertussis is part of national immunisation programmes in the EU.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija pret garo klepu ir daļa no valstu imunizācijas programmām ES.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="357"> |
|
<prop type="lengthRatio">1.043859649122807</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, during 2018 about 86% of infants worldwide received three doses of the vaccine that protects them against diphtheria, tetanus and pertussis (DTP), and 85% of infants around the world received three doses of polio vaccine (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, 2018. gadā aptuveni 86 % zīdaiņu visā pasaulē saņēma trīs devas ar vakcīnu, kas aizsargā viņus pret difteriju, stingumkrampjiem un garo klepu, un 85 % zīdaiņu visā pasaulē saņēma trīs devas ar poliomielīta vakcīnu (1).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="358"> |
|
<prop type="lengthRatio">0.9791666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>If people stopped being vaccinated, many of these diseases and related outbreaks could return.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ja cilvēki pārtrauktu vakcinēties, daudzas slimības un ar tām saistītie uzliesmojumi atgrieztos.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="359"> |
|
<prop type="lengthRatio">0.9928571428571429</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Many infectious diseases are very rare today thanks to vaccination, so the negative consequences of these diseases are sometimes forgotten.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pateicoties vakcinācijai, mūsdienās daudzas infekcijas slimības ir ļoti retas, tāpēc reizēm tiek aizmirsts par šo slimību negatīvajām sekām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="360"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines prevent diseases that could otherwise cause serious health problems, permanent disability or even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas novērš slimības, kas varētu izraisīt nopietnas veselības problēmas, pastāvīgu invaliditāti vai pat nāvi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="361"> |
|
<prop type="lengthRatio">1.0909090909090908</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This protects children from whooping cough, while it only causes minor side effects.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā aizsargā bērnus pret garo klepu, un tai ir tikai nelielas blakusparādības.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="362"> |
|
<prop type="lengthRatio">1.00990099009901</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications can include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Var būt arī tādas komplikācijas kā pneimonija, encefalopātija (smadzeņu slimība), lēkmes un pat nāve.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="363"> |
|
<prop type="lengthRatio">1.2428571428571429</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Therefore, the long-term benefits of getting vaccinated may not be immediately obvious.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tāpēc ne vienmēr var uzreiz novērot vakcinācijas ilgtermiņa ieguvumus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="364"> |
|
<prop type="lengthRatio">0.8275862068965517</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles can be serious or even life-threatening.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masalas var būt nopietna vai pat dzīvībai bīstama slimība.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="365"> |
|
<prop type="lengthRatio">1.0081967213114753</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Unlike a treatment given to cure an illness, vaccines are usually given to healthy people to prevent them from getting ill.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Atšķirībā no citām zālēm, ko izraksta slimības ārstēšanai, vakcīnas parasti saņem veseli cilvēki, lai novērstu saslimšanu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="366"> |
|
<prop type="lengthRatio">0.8653846153846154</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information, see measles factsheet .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāku informāciju skatiet faktu lapā par masalām .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="367"> |
|
<prop type="lengthRatio">1.1323529411764706</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine protects against measles, mumps and rubella (German measles).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>MMR vakcīna aizsargā pret masalām, epidēmisko parotītu un masaliņām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="368"> |
|
<prop type="lengthRatio">0.8545454545454545</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information, see pertussis factsheet .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāku informāciju skatiet faktu lapā par garo klepu .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="369"> |
|
<prop type="lengthRatio">1.4090909090909092</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis (whooping cough) is a disease affecting the airways.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Garais klepus ir slimība, kas skar elpceļus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="370"> |
|
<prop type="lengthRatio">1.4090909090909092</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemērs: garais klepus</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="371"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About us</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Par mums</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="372"> |
|
<prop type="lengthRatio">1.1904761904761905</prop> |
|
<tuv xml:lang="en"> |
|
<seg>European Medicines Agency</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Eiropas Zāļu aģentūra</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="373"> |
|
<prop type="lengthRatio">1.3454545454545455</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The European Commission is the EU's politically independent executive arm.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Eiropas Komisija ir ES politiski neatkarīga izpildvara.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="374"> |
|
<prop type="lengthRatio">1.1690140845070423</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The Commission is divided into departments that develop policies in specific areas.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Komisiju iedala departamentos, kas izstrādā politiku specifiskās jomās.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="375"> |
|
<prop type="lengthRatio">1.1818181818181819</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Communication and scientific experts in these organisations are involved in developing the contents (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šo organizāciju komunikācijas un zinātniskie eksperti ir iesaistīti satura izstrādē (1).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="376"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These experts carry out the work of EMA's scientific committees.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šie eksperti veic EMA zinātnisko komiteju darbu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="377"> |
|
<prop type="lengthRatio">1.0638297872340425</prop> |
|
<tuv xml:lang="en"> |
|
<seg>European Centre for Disease Prevention and Control</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Eiropas Slimību profilakses un kontroles centrs</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="378"> |
|
<prop type="lengthRatio">1.3983050847457628</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is alone responsible for drawing up proposals for new European legislation, and it implements the decisions of the European Parliament and the Council of the EU .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā atbild par priekšlikumu izstrādi jauniem Eiropas tiesību aktiem un īsteno Eiropas Parlamenta un ES Padomes lēmumus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="379"> |
|
<prop type="lengthRatio">1.1647058823529413</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(1) The European Commission, ECDC and EMA have mechanisms in place in order to ensure impartiality.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>(1) Eiropas Komisijā, ECDC un EMA ir ieviesti mehānismi, kas nodrošina objektivitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="380"> |
|
<prop type="lengthRatio">0.8909090909090909</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>EMA ir uz sadarbību orientēta organizācija, kuras darbībās ir iesaistīti tūkstošiem ekspertu no visas Eiropas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="381"> |
|
<prop type="lengthRatio">0.9919354838709677</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA works closely with European and international partners and shares information on vaccines and good regulatory practice.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>EMA cieši sadarbojas ar Eiropas un starptautiskajiem partneriem un dalās informācijā par vakcīnām un labu regulatīvo praksi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="382"> |
|
<prop type="lengthRatio">1.0246305418719213</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is to ensure that staff and experts do not, in the performance of their duties, deal with matters in which they may, directly or indirectly, have a personal interest that could impair their independence.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas nepieciešams, lai nodrošinātu, ka darbinieki un eksperti savu pienākumu izpildē neizskata jautājumus, kuros viņiem varētu būt tieša vai netieša personīga interese, kas varētu mazināt viņu neatkarību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="383"> |
|
<prop type="lengthRatio">0.9815950920245399</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA and its scientific committees examine all available data and assess their benefits and risks before they are approved and while they are marketed in the EU.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>EMA un tās zinātniskās komitejas pārbauda visus pieejamos datus un novērtē vakcīnu ieguvumus un riskus, pirms tās tiek apstiprinātas un kamēr tās tiek tirgotas ES.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="384"> |
|
<prop type="lengthRatio">0.9805825242718447</prop> |
|
<tuv xml:lang="en"> |
|
<seg>ECDC is an EU scientific agency aimed at strengthening Europe's defences against infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>ECDC ir ES zinātniskā aģentūra, kuras mērķis ir stiprināt Eiropas aizsardzību pret infekcijas slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="385"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA ensures the efficacy, quality and safety of vaccines.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>EMA nodrošina vakcīnu efektivitāti, kvalitāti un drošumu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="386"> |
|
<prop type="lengthRatio">1.098360655737705</prop> |
|
<tuv xml:lang="en"> |
|
<seg>ECDC also maintains the Vaccine Scheduler , an online, interactive platform showing the vaccination schedules of all EU Member States.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>ECDC arī uztur vakcīnu plānotāju - interaktīvu tiešsaistes platformu, kurā sniegti visu ES dalībvalstu vakcinācijas plāni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="387"> |
|
<prop type="lengthRatio">0.9503105590062112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Staff and experts are required to declare any personal interest or any interest in any business or organisation that could compromise their impartiality.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Darbiniekiem un ekspertiem ir jāinformē par jebkādu personīgo interesi vai jebkādu interesi uzņēmumā vai organizācijā, kas varētu ietekmēt ar viņu objektivitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="388"> |
|
<prop type="lengthRatio">1.1192660550458715</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This website was developed by the European Centre for Disease Prevention and Control (ECDC), in partnership with the European Commission, specifically, its Department on Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šo tīmekļa vietni izstrādāja Eiropas Slimību profilakses un kontroles centrs (ECDC) sadarbībā ar Eiropas Komisiju, proti, ar tās Veselības un pārtikas nekaitīguma departamentu (DG SANTE) un Eiropas Zāļu aģentūru (EMA).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="389"> |
|
<prop type="lengthRatio">1.0495867768595042</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination in general.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šīs tīmekļa vietnes galvenais mērķis ir sniegt precīzus, objektīvus un aktuālus pierādījumus par vakcīnām un vakcināciju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="390"> |
|
<prop type="lengthRatio">1.173913043478261</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The European Medicines Agency (EMA) is a decentralized agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Eiropas Zāļu aģentūra (EMA) ir decentralizēta Eiropas Savienības (ES) aģentūra, kas atbild par zinātnisko novērtējumu, uzraudzību un drošuma uzraudzību zālēm ES.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="391"> |
|
<prop type="lengthRatio">0.9201388888888888</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The core functions cover a wide spectrum of activities: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Galvenās funkcijas aptver plašu darbību klāstu: uzraudzību, epidemioloģisko informāciju, reaģēšanu, zinātniskas konsultācijas, mikrobioloģiju, sagatavotību, mācības sabiedrības veselības jomā, starptautiskās attiecības, komunikāciju veselības jomā un zinātnisko izdevumu Eurosurveillance.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="392"> |
|
<prop type="lengthRatio">0.8913043478260869</prop> |
|
<tuv xml:lang="en"> |
|
<seg>One of the departments is DG for Health and Food Safety , responsible for EU policy on food safety and health and for monitoring the implementation of related laws.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Viens no departamentiem ir Veselības un pārtikas nekaitīguma ĢD , kas atbild par ES politiku veselības un pārtikas nekaitīguma jomā un par saistīto tiesību aktu īstenošanas uzraudzību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="393"> |
|
<prop type="lengthRatio">0.9848484848484849</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Read more: https://ec.europa.eu/health/vaccination/overview_en and https://ec.europa.eu/info/departments/health-and-food-safety_en</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lasīt vairāk: https://ec.europa.eu/health/vaccination/overview_lv un https://ec.europa.eu/info/departments/health-and-food-safety_lv</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="394"> |
|
<prop type="lengthRatio">0.992</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In the area of vaccine-preventable diseases, ECDC provides regular surveillance data, e.g. the number of confirmed cases, and scientific advice on vaccines, monitors disease outbreaks and develops materials to support communication on immunisation.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnnovēršamu slimību jomā ECDC sniedz regulārus uzraudzības datus, piemēram, apstiprināto gadījumu skaitu, un zinātniskas konsultācijas par vakcīnām, uzrauga slimību uzliesmojumus un sagatavo materiālus, lai atbalstītu informēšanu par imunizāciju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="395"> |
|
<prop type="lengthRatio">0.9130434782608695</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Iniciatīvas mērķis ir mazināt šaubas par vakcīnas saņemšanu, uzlabot koordināciju vakcīnu iegādes jomā, atbalstīt pētniecību un inovāciju un stiprināt ES sadarbību, kas vērsta pret vakcīnnovēršamām slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="396"> |
|
<prop type="lengthRatio">0.9493670886075949</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Representatives from EU and EEA countries' public health organisations were consulted for finalising the website's contents and its language versions.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lai pabeigtu tīmekļa vietnes saturu un tās valodu versijas, tika rīkotas konsultācijas ar pārstāvjiem no ES un EEZ valstu sabiedrības veselības organizācijām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="397"> |
|
<prop type="lengthRatio">0.9946808510638298</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is an initiative of the European Union and was developed following the Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases adopted in December 2018.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā ir Eiropas Savienības iniciatīva, kura tika izstrādāta saskaņā ar Padomes Ieteikumu par pastiprinātu sadarbību, kas vērsta pret vakcīnnovēršamām slimībām (pieņemts 2018. gada decembrī).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="398"> |
|
<prop type="lengthRatio">1.1702127659574468</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information visit: https://www.ema.europa.eu /</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sīkāka informācija: https://www.ema.europa.eu /</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="399"> |
|
<prop type="lengthRatio">0.8982035928143712</prop> |
|
<tuv xml:lang="en"> |
|
<seg>To improve vaccination uptake, the Council adopted a Recommendation to strengthen the EU cooperation on vaccine-preventable diseases in December 2018.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lai vairotu vakcināciju popularitāti, Padome pieņēma Ieteikumu par pastiprinātu ES sadarbību, kas vērsta pret vakcīnnovēršamām slimībām (pieņemts 2018. gada decembrī).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="400"> |
|
<prop type="lengthRatio">1.1702127659574468</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information visit: https://www.ecdc.europa.eu/</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Sīkāka informācija: https://www.ecdc.europa.eu/</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="401"> |
|
<prop type="lengthRatio">0.9557522123893806</prop> |
|
<tuv xml:lang="en"> |
|
<seg>National governments take account of factors such as their health systems, legal systems and cultural norms.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Valstu valdības ņem vērā tādus faktorus, kā to veselības aprūpes sistēmas, tiesiskās sistēmas un kultūras normas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="402"> |
|
<prop type="lengthRatio">1.0588235294117647</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mandatory or recommended vaccination</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Obligāta vai ieteicama vakcinācija</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="403"> |
|
<prop type="lengthRatio">1.1149425287356323</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information on which countries have mandatory vaccination can be found in the Vaccine Scheduler .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Informācija par valstīm, kurās vakcinācija ir obligāta, ir atrodama Vakcīnu plānotājā .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="404"> |
|
<prop type="lengthRatio">1.1272727272727272</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each EU/EEA country implements its own immunisation programme.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katra ES/EEZ valsts īsteno savu imunizācijas programmu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="405"> |
|
<prop type="lengthRatio">1.2727272727272727</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In 12 EU/EEA countries, vaccinating children against some diseases is mandatory, although different vaccines are required as mandatory in those countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>12 ES/EEZ valstīs bērnu vakcinācija pret dažām slimībām ir obligāta, lai arī šajās valstīs obligātas ir dažādas vakcīnas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="406"> |
|
<prop type="lengthRatio">0.9555555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each EU/EEA country decides if vaccination is mandatory or voluntary in its territory.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katra ES/EEZ valsts izlemj, vai vakcinācija ir obligāta vai brīvprātīga valsts teritorijā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="407"> |
|
<prop type="lengthRatio">1.0571428571428572</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EU/EEA countries have achieved high vaccination coverage rates through mandatory and non-mandatory vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>ES/EEZ valstis ir panākušas augstu vakcinācijas seguma līmeni, veicot obligātu un neobligātu vakcināciju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="408"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most EU/EEA countries offer vaccination on a recommended basis.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lielākā daļa ES/EEZ valstu ieteicamā kārtā piedāvā vakcināciju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="409"> |
|
<prop type="lengthRatio">0.5833333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These include:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tie citu starpā ir šādi:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="410"> |
|
<prop type="lengthRatio">1.032</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It typically provides lifelong protection and has an effectiveness of around 97-99% among healthy children who receive two doses.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā parasti nodrošina aizsardzību visu mūžu, un tai ir aptuveni 97-99 % efektivitāte veseliem bērniem, kuri saņem divas devas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="411"> |
|
<prop type="lengthRatio">0.9148936170212766</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They are also less likely to infect others.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Viņiem arī pastāv mazāka iespēja inficēt citus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="412"> |
|
<prop type="lengthRatio">0.96875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Effectiveness in an individual depends on a number of factors.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Efektivitāte katram cilvēkam ir atkarīga no vairākiem faktoriem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="413"> |
|
<prop type="lengthRatio">0.8210526315789474</prop> |
|
<tuv xml:lang="en"> |
|
<seg>As with any medicine, no vaccine is 100% effective in every person vaccinated.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tāpat kā jebkuras citas zāles, neviena vakcīna nav 100 % efektīva katram vakcinētajam cilvēkam.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="414"> |
|
<prop type="lengthRatio">0.8269230769230769</prop> |
|
<tuv xml:lang="en"> |
|
<seg>other diseases or conditions they may have;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>citas slimības vai traucējumi, kas viņam varētu būt;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="415"> |
|
<prop type="lengthRatio">1.025</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is due to the person not developing sufficient protection against the disease or due to immunity decreasing over time.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā notiek tāpēc, ka cilvēkam nav izstrādājusies pietiekama aizsardzība pret slimību vai imunitāte laika gaitā pazeminās.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="416"> |
|
<prop type="lengthRatio">1.0091743119266054</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In these cases, however, the person's symptoms are often milder than they would have been without vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr šādos gadījumos cilvēka simptomi bieži vien ir vieglāki nekā tad, ja vispār nebūtu saņemta vakcinācija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="417"> |
|
<prop type="lengthRatio">1.1826923076923077</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some circumstances, a person can still get a disease even after receiving the recommended doses of a vaccine against it.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažos gadījumos cilvēks tik un tā var saslimt, pat ja ir saņēmis ieteicamās vakcīnas devas pret slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="418"> |
|
<prop type="lengthRatio">1.0285714285714285</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, the vaccine against measles, mumps and rubella (MMR) is highly effective at preventing disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, vakcīna pret masalām, epidēmisko parotītu un masaliņām (MMR) ļoti efektīvi novērš šīs slimības.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="419"> |
|
<prop type="lengthRatio">1.5</prop> |
|
<tuv xml:lang="en"> |
|
<seg>the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>vakcīna.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="420"> |
|
<prop type="lengthRatio">1.234375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas efektivitāti nosaka tās spēja novērst konkrētu slimību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="421"> |
|
<prop type="lengthRatio">1.2127659574468086</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Authorised vaccines are effective at preventing disease and protecting the population when administered correctly.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Reģistrētās vakcīnas, ja tās ievada pareizi, efektīvi novērš slimību un aizsargā iedzīvotājus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="422"> |
|
<prop type="lengthRatio">0.9615384615384616</prop> |
|
<tuv xml:lang="en"> |
|
<seg>how the vaccine is given;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>vakcīnas lietošanas veids;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="423"> |
|
<prop type="lengthRatio">1.4166666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>previous contact with the disease;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>laiks kopš vakcinēšanas;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="424"> |
|
<prop type="lengthRatio">1.148936170212766</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Children are infected slightly more often than adults.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Bērni inficējas nedaudz biežāk nekā pieaugušie.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="425"> |
|
<prop type="lengthRatio">1.048780487804878</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Patients are advised to seek medical advice if their condition continues to get worse.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pacientiem iesaka konsultēties ar ārstu, ja viņu stāvoklis turpina pasliktināties.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="426"> |
|
<prop type="lengthRatio">0.9060402684563759</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Even so, about half of the children and working-age adults needing admission to intensive care have no pre-existing medical conditions.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Neraugoties uz to, aptuveni pusei bērnu un darbspējas vecuma pieaugušo, kuriem nepieciešama intensīvā aprūpe, nav bijis jau esošu veselības problēmu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="427"> |
|
<prop type="lengthRatio">0.9625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These epidemics are associated with high hospitalisation rates and mortality.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šīs epidēmijas ir saistītas ar augstiem hospitalizācijas rādītājiem un mirstību.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="428"> |
|
<prop type="lengthRatio">1.1415929203539823</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Approximately 20% of the population gets infected with influenza each year and one in four infected people will develop symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Aptuveni 20 % iedzīvotāju katru gadu inficējas ar gripu, un vienam no četriem inficētajiem būs slimības simptomi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="429"> |
|
<prop type="lengthRatio">0.8875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The 2009 A(H1N1)pdm09 influenza pandemic accounted for 123 000 to 203 000 deaths worldwide and a significant global socio-economic burden (3).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>2009. gadā A(H1N1)pdm09 gripas pandēmijas dēļ visā pasaulē kopumā mira 123 000 līdz 203 000 cilvēku, un tā radīja ievērojamu globālo sociālekonomisko slogu (3).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="430"> |
|
<prop type="lengthRatio">1.1088435374149659</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most EU Member States follow the WHO recommendations to vaccinate pregnant women, and some follow recommendations to vaccinate healthy children aged 6 - 59 months.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lielākā daļa ES dalībvalstu ievēro PVO ieteikumu vakcinēt grūtnieces, un dažas valstis ievēro ieteikumu vakcinēt veselus bērnus 6-59 mēnešu vecumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="431"> |
|
<prop type="lengthRatio">0.6135265700483091</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(1) EuroMOMO - European monitoring of excess mortality for public health action: http://www.euromomo.eu/methods/objectives.html</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>(1) EuroMOMO - Eiropas paaugstinātas mirstības uzraudzība rīcībai sabiedrības veselības jomā (European monitoring of excess mortality for public health action): http://www.euromomo.eu/methods/objectives.html</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="432"> |
|
<prop type="lengthRatio">0.9456521739130435</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The World Health Organization (WHO) also recommends vaccination for healthcare workers.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pasaules Veselības organizācija (PVO) vakcināciju iesaka arī veselības aprūpes darbiniekiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="433"> |
|
<prop type="lengthRatio">1.0727272727272728</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination is the most effective way to prevent influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija ir visefektīvākais gripas novēršanas veids.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="434"> |
|
<prop type="lengthRatio">1.2830188679245282</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Not everyone who is infected with an influenza virus becomes unwell.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ne visi, kuri inficēti ar gripas vīrusu, jūtas slimi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="435"> |
|
<prop type="lengthRatio">1.148936170212766</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Influenza is easily transmitted from person to person.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Gripu var viegli pārnest no cilvēka uz cilvēku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="436"> |
|
<prop type="lengthRatio">1.1282051282051282</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The mortality rate due to influenza has been estimated in the EU/EEA countries participating to the EuroMOMO network (1) to be as high as 25 deaths per 100 000 population in the 2016/27 and 2017/18 influenza seasons (2).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tiek lēsts, ka mirstības rādītājs gripas dēļ ES/EEZ valstīs, kas piedalās EuroMOMO tīklā (1), ir 25 nāves gadījumi uz 100 000 iedzīvotājiem 2016./2017. gada un 2017./2018. gada gripas sezonā (2).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="437"> |
|
<prop type="lengthRatio">1.1578947368421053</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Animals can also be infected with influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Arī dzīvnieki var inficēties ar gripu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="438"> |
|
<prop type="lengthRatio">0.9247311827956989</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, antivirals are generally recommended for severe or rapidly progressing cases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tomēr pretvīrusu zāles parasti iesaka smagos vai strauji progresējošos saslimšanas gadījumos.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="439"> |
|
<prop type="lengthRatio">1.1</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In Europe, influenza occurs in regular annual epidemics in the winter season.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Eiropā gripa izpaužas kā regulāras ikgadējas epidēmijas ziemas sezonā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="440"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>sore throat;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>sāpes kaklā;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="441"> |
|
<prop type="lengthRatio">0.9761904761904762</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is also spread via secretions on hands, tissues and surfaces that people touch.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā izplatās arī ar sekrētiem uz plaukstām, audiem un virsmām, kam cilvēki pieskaras.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="442"> |
|
<prop type="lengthRatio">0.8531468531468531</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Severe illness and complications are more common in very young infants, the frail elderly and certain medical risk groups.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Smaga slimība un komplikācijas biežāk novēro ļoti jauniem zīdaiņiem, slimīgiem veca gadagājuma cilvēkiem un noteiktām medicīniskā riska grupām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="443"> |
|
<prop type="lengthRatio">0.9801587301587301</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The EU Member States recommend seasonal influenza vaccination for risk groups, such as the elderly, as well as individuals with chronic medical conditions like heart disease, problems with the lungs and airways, diabetes or immune system problems.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>ES dalībvalstis iesaka saņemt sezonālu gripas vakcināciju riska grupām, piemēram, vecāka gadagājuma cilvēkiem, kā arī cilvēkiem ar hroniskām veselības problēmām, tādām kā sirds slimības, plaušu vai elpceļu problēmas, diabēts vai imūnsistēmas problēmas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="444"> |
|
<prop type="lengthRatio">0.956140350877193</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāka informācija pieejama ECDC tīmekļa vietnē: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="445"> |
|
<prop type="lengthRatio">1.2162162162162162</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications of influenza include pneumonia and encephalitis (inflammation of the brain).</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Gripas komplikācijas ietver pneimoniju un encefalītu (smadzeņu iekaisumu).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="446"> |
|
<prop type="lengthRatio">1.0445544554455446</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition to vaccination, antiviral medicines have been shown to be safe and effective measures to prevent influenza infection or to reduce the severity of infection in certain settings, such as nursing homes.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ir pierādīts, ka papildus vakcīnām drošs un efektīvs līdzeklis ir arī pretvīrusu zāles, lai novērstu gripas infekciju vai mazinātu infekcijas smaguma pakāpi noteiktās vietās, piemēram, aprūpes iestādēs.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="447"> |
|
<prop type="lengthRatio">0.9312977099236641</prop> |
|
<tuv xml:lang="en"> |
|
<seg>People with pre-existing medical conditions are at higher risk of their condition worsening following influenza infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēkiem ar jau esošām veselības problēmām pastāv lielāks risks, ka pēc gripas infekcijas viņu veselības stāvoklis pasliktināsies.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="448"> |
|
<prop type="lengthRatio">1.028169014084507</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A pandemic is the rapid spread of a new human influenza around the world.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pandēmija ir jauna cilvēku gripas veida strauja izplatība visā pasaulē.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="449"> |
|
<prop type="lengthRatio">0.7962962962962963</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For those that do, common symptoms include:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēkiem, kuri jūtas slikti, visbiežākie simptomi ir:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="450"> |
|
<prop type="lengthRatio">1.0404040404040404</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition to seasonal epidemics, novel influenza viruses may occasionally emerge and cause pandemics.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Papildus sezonālām epidēmijām, dažkārt var rasties jauni gripas vīrusa veidi un izraisīt pandēmiju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="451"> |
|
<prop type="lengthRatio">0.9466666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The EU Council Recommendation on seasonal influenza vaccination encourages countries to improve vaccination coverage among healthcare workers.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>ES Padomes Ieteikumā par vakcināciju pret sezonālo gripu valstis tiek mudinātas palielināt vakcinēto cilvēku skaitu veselības aprūpes darbinieku vidū.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="452"> |
|
<prop type="lengthRatio">1.0964912280701755</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some cases patients develop bacterial complications following influenza infection and need to be treated with antibiotics.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažos gadījumos pacientiem pēc gripas infekcijas rodas bakteriālas komplikācijas, un viņi jāārstē ar antibiotikām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="453"> |
|
<prop type="lengthRatio">1.0391061452513966</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Influenza pandemics happen when a new strain of a flu virus appears which can infect humans, to which most people have no immunity and which can transmit efficiently from human to human.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Gripas pandēmijas gadījumā rodas jauns gripas vīrusa celms, kas var skart cilvēkus, pret ko lielākajai daļai cilvēku nav imunitātes un ko var viegli pārnest no cilvēka uz cilvēku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="454"> |
|
<prop type="lengthRatio">0.9029126213592233</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The severity of the disease varies widely, from no symptoms at all through to severe illness.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Slimības nopietnības pakāpes var būt ļoti dažādas - no slimības bez simptomiem līdz smagai saslimšanai.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="455"> |
|
<prop type="lengthRatio">1.0105263157894737</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some cases, humans can be infected by animals, such as in cases of avian and swine influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažos gadījumos dzīvnieki var inficēt cilvēkus, piemēram, putnu gripas un cūku gripas gadījumā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="456"> |
|
<prop type="lengthRatio">0.9530201342281879</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is mainly via direct contact with secretions from infectious patients, such as droplets of fluid released when they cough or breathe out.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tas galvenokārt notiek, nonākot tiešā saskarē ar inficēto pacientu sekrētiem, piemēram, šķidruma pilieniem, kas rodas, viņiem klepojot vai izelpojot.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="457"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is influenza spread?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā gripa izplatās?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="458"> |
|
<prop type="lengthRatio">1.263157894736842</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Influenza (flu) is a contagious respiratory illness caused by infection with an influenza virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Gripa ir lipīga elpceļu saslimšana, ko izraisa inficēšanās ar gripas vīrusu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="459"> |
|
<prop type="lengthRatio">0.9318181818181818</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vieglos gadījumos simptomi izzūd bez ārstēšanas nedēļas laikā pēc saslimšanas ar vīrusu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="460"> |
|
<prop type="lengthRatio">0.8</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurām personām pastāv gripas risks?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="461"> |
|
<prop type="lengthRatio">1.6875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For most cases of influenza, patients are advised to take bed rest and drink plenty of fluids in order to manage their symptoms; staying at home also minimises the risk of infecting others.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vairumā gripas gadījumu pacientiem iesaka ievērot gultas režīmu un dzert daudz šķidruma, lai mazinātu simptomus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="462"> |
|
<prop type="lengthRatio">1.030612244897959</prop> |
|
<tuv xml:lang="en"> |
|
<seg>An update of seasonal influenza vaccines is needed yearly, since influenza viruses constantly evolve.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tā kā gripas vīrusi pastāvīgi attīstās, ik gadu ir nepieciešams atjaunot sezonālās gripas vakcīnu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="463"> |
|
<prop type="lengthRatio">1.4761904761904763</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can influenza be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā var novērst gripu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="464"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir gripas komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="465"> |
|
<prop type="lengthRatio">1.3846153846153846</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kas ir gripa?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="466"> |
|
<prop type="lengthRatio">1.0806451612903225</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antiviral medicines, taken as rapidly as possible after illness onset, are safe and effective measures for the treatment of influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pretvīrusu zāles ir drošs un efektīvs gripas ārstēšanas līdzeklis, ja, sākoties slimībai, tās sāk lietot pēc iespējas ātrāk.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="467"> |
|
<prop type="lengthRatio">1.4583333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir gripas simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="468"> |
|
<prop type="lengthRatio">1.6666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is influenza treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā ārstē gripu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="469"> |
|
<prop type="lengthRatio">1.6153846153846154</prop> |
|
<tuv xml:lang="en"> |
|
<seg>non-productive cough.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>sauss klepus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="470"> |
|
<prop type="lengthRatio">2.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841239/</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēka papilomas vīruss (HPV)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="471"> |
|
<prop type="lengthRatio">1.1363636363636365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some countries such recommendations are done at state or regional level.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažās valstīs šādus ieteikumus sniedz valsts vai reģionālā līmenī.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="472"> |
|
<prop type="lengthRatio">1.0634920634920635</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They also provide recommendations for people with chronic diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Tajos arī ir sniegti ieteikumi cilvēkiem ar hroniskām slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="473"> |
|
<prop type="lengthRatio">1.043859649122807</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When looking at health-related information, it can be difficult to judge the quality and accuracy of information found.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Aplūkojot ar veselību saistītu informāciju, var būt grūti novērtēt atrastās informācijas kvalitāti un precizitāti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="474"> |
|
<prop type="lengthRatio">1.0161290322580645</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This section provides links to the websites of other health organisations both at national and international level, in order to facilitate access to trusted sources of information, such as:</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Šajā sadaļā ir saites uz citu veselības aizsardzības organizāciju tīmekļa vietnēm gan valsts, gan starptautiskā līmenī, lai atvieglotu piekļuvi uzticamiem informācijas avotiem, piemēram:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="475"> |
|
<prop type="lengthRatio">1.0238095238095237</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Official websites from EU and EEA countries</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>ES un EEZ valstu oficiālās tīmekļa vietnes</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="476"> |
|
<prop type="lengthRatio">1.2195121951219512</prop> |
|
<tuv xml:lang="en"> |
|
<seg>More factsheets will be included at a later stage.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vēlāk tiks iekļautas papildu faktu lapas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="477"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The Vaccine Safety Net (VSN) is a global network of websites, established by the World Health Organization, that provides reliable information on vaccine safety.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu drošuma tīkls (VDT) ir globāls tīmekļa vietņu tīkls, ko izveidojusi Pasaules Veselības organizācija un kas sniedz ticamu informāciju par vakcīnu drošumu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="478"> |
|
<prop type="lengthRatio">1.015267175572519</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are recommended for different age groups, often for infants and children, but also for teenagers, adults and elderly people.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnas iesaka dažādām vecuma grupām, nereti zīdaiņiem un bērniem, taču arī pusaudžiem, pieaugušajiem un gados vecākiem cilvēkiem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="479"> |
|
<prop type="lengthRatio">1.0066666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Healthcare professionals (e.g. doctors, nurses) have a role in ensuring that patients in their care receive the recommended vaccines at the right time.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Veselības aprūpes speciālistu (piemēram, ārstu, māsu) uzdevums ir nodrošināt, ka viņu aprūpē esošie pacienti saņem ieteiktās vakcīnas pareizajā laikā.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="480"> |
|
<prop type="lengthRatio">0.9795918367346939</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccines are not part of routine vaccination schedules but are targeted at specific groups.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažas vakcīnas nav ietvertas kārtējās vakcinācijas grafikos, taču tās paredzētas konkrētām grupām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="481"> |
|
<prop type="lengthRatio">1.0050251256281406</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each factsheet provides key facts about a disease, with an overview of the symptoms, complications, how the disease spreads, who is at risk, how the disease can be prevented and how it can be treated.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Katrā faktu lapā ir sniegti galvenie fakti par slimību, kā arī pārskats par simptomiem, komplikācijām, slimības izplatīšanos, riskam pakļauto personu loku, par to, kā slimību novērst un kā to ārstēt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="482"> |
|
<prop type="lengthRatio">1.2027027027027026</prop> |
|
<tuv xml:lang="en"> |
|
<seg>People may wonder where to find accurate information, who is behind the development of the information they find, and also if the information is supported by scientific evidence.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēki var rasties jautājums, kurai meklē precīzu informāciju, kas ir atrastās informācijas pamatā, kā arī, vai informācija ir zinātniski pamatota.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="483"> |
|
<prop type="lengthRatio">0.990990990990991</prop> |
|
<tuv xml:lang="en"> |
|
<seg>To learn more about the diseases that can be prevented by vaccination, consult the factsheets available below.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Lai uzzinātu vairāk par slimībām, kuras var novērst vakcinējoties, iepazīstieties ar pievienotajām faktu lapām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="484"> |
|
<prop type="lengthRatio">0.9647887323943662</prop> |
|
<tuv xml:lang="en"> |
|
<seg>With all the information that is available on the internet and circulating on social media on vaccination, people may sometimes get lost.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Ar visu internetā pieejamo un sociālajos plašsaziņas līdzekļos izplatīto informāciju par vakcināciju cilvēkiem dažkārt var rasties nesapratne.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="485"> |
|
<prop type="lengthRatio">0.9148936170212766</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Below are links to official websites with information on vaccination from public health organisations of the European Union (EU) and European Economic Area (EEA) countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Zemāk redzamas saites uz oficiālajām tīmekļa vietnēm ar informāciju par vakcināciju no Eiropas Savienības (ES) un Eiropas Ekonomikas zonas (EEZ) valstu sabiedrības veselības organizācijām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="486"> |
|
<prop type="lengthRatio">1.02</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The only protection against measles is vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vienīgā aizsardzība pret masaliņām ir vakcinācija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="487"> |
|
<prop type="lengthRatio">1.0727272727272728</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Nowadays, several diseases can be prevented by vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Mūsdienās ar vakcināciju var novērst vairākas slimības.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="488"> |
|
<prop type="lengthRatio">1.2714285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination also reduces the risk of spreading the diseases among family members, school mates or colleagues, friends and neighbours, as well as to other people in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcinācija arī mazina risku slimības izplatībai ģimenes locekļu, skolasbiedru vai kolēģu, draugu un kaimiņu vidū, kā arī sabiedrībā vispār.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="489"> |
|
<prop type="lengthRatio">0.9586776859504132</prop> |
|
<tuv xml:lang="en"> |
|
<seg>National vaccination schedules in EU/EEA countries recommend vaccines at specific ages and for specific populations.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Valsts vakcinācijas grafikos ES/EEZ valstīs tiek rekomendētas vakcīnas konkrētos vecumos un konkrētām iedzīvotāju grupām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="490"> |
|
<prop type="lengthRatio">1.028169014084507</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Factsheets of five vaccine- preventable diseases are currently available.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pašlaik ir pieejamas faktu lapas par piecām vakcīnregulējamām slimībām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="491"> |
|
<prop type="lengthRatio">1.063063063063063</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Thanks to vaccination, people can be protected against diseases that could have serious consequences for their health.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pateicoties vakcinācijai, cilvēki var tikt aizsargāti pret slimībām, kuras var radīt nopietnas sekas veselībai.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="492"> |
|
<prop type="lengthRatio">0.7894736842105263</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some countries require proof of certain vaccinations before granting entry to the country.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Dažās valstīs, lai saņemtu atļauju tajās ieceļot, ir nepieciešams pierādījums par noteiktām saņemtām vakcinācijām.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="493"> |
|
<prop type="lengthRatio">0.9281437125748503</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, people who travel to regions where certain infectious diseases circulate such as yellow fever and typhoid fever may need to have vaccinations.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Piemēram, vakcinēties var būt nepieciešams cilvēkiem, kuri ceļo uz reģioniem, kuros ir izplatītas noteiktas infekcijas slimības, piemēram, dzeltenais drudzis vai tīfs.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="494"> |
|
<prop type="lengthRatio">1.1153846153846154</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can rubella be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā var novērst garo klepu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="495"> |
|
<prop type="lengthRatio">1.0857142857142856</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir garā klepus komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="496"> |
|
<prop type="lengthRatio">0.5777777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurš ir pakļauts riskam saslimt ar masaliņām?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="497"> |
|
<prop type="lengthRatio">1.3461538461538463</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is also known as whooping cough.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>To arī dēvē par Pertussis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="498"> |
|
<prop type="lengthRatio">1.2560975609756098</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The measles virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masaliņu vīruss izplatās gaisa pilienu ceļā, kad inficētā persona klepo un šķauda.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="499"> |
|
<prop type="lengthRatio">0.5816326530612245</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Plašāku informāciju par tīklu skatiet šeit: https://vaccinesafetynet.org . Informācija un saites uz VDT dalībnieku tīmekļa vietnēm ir pieejamas šeit: https://www.vaccinesafetynet.org/vsn/network .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="500"> |
|
<prop type="lengthRatio">0.9032258064516129</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurš ir pakļauts masalu riskam?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="501"> |
|
<prop type="lengthRatio">1.2</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Clinical Microbiology and Infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Masaliņas ir vīrusa infekcija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="502"> |
|
<prop type="lengthRatio">1.3157894736842106</prop> |
|
<tuv xml:lang="en"> |
|
<seg>how the vaccine is given;</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu plānotājā .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="503"> |
|
<prop type="lengthRatio">0.8913043478260869</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccination for the community</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīnu drošuma tīkls (The Vaccine Safety Net)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="504"> |
|
<prop type="lengthRatio">0.65</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kurām personām pastāv garā klepus risks?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="505"> |
|
<prop type="lengthRatio">0.8378378378378378</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Are there serious side effects?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>drudzis vai drudzim līdzīgi simptomi;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="506"> |
|
<prop type="lengthRatio">0.8378378378378378</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>dzimumorgānu un anālās atveres kārpas</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="507"> |
|
<prop type="lengthRatio">0.7708333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>PLoS Med. 2013 Nov; 10(11): e1001558.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>PLoS Med. 2013. gada novembris,10(11): e1001558.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="508"> |
|
<prop type="lengthRatio">1.0204081632653061</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Avots: Plotkin S, Orenstein W, Offit P. Vaccines.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="509"> |
|
<prop type="lengthRatio">1.0476190476190477</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Vakcīna dažiem cilvēkiem var būt kontrindicēta, proti, viņiem to nevajadzētu saņemt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="510"> |
|
<prop type="lengthRatio">0.8666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Human papillomavirus (HPV)</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Cilvēka papilomas vīruss (HPV)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="511"> |
|
<prop type="lengthRatio">1.0377358490566038</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Pirms vakcīnas saņemšanas vienmēr ar veselības aprūpes speciālistu jāapspriež iespējamās kontrindikācijas.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="512"> |
|
<prop type="lengthRatio">1.16</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can measles be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā var novērst masaliņas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="513"> |
|
<prop type="lengthRatio">1.1875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir masaliņu komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="514"> |
|
<prop type="lengthRatio">1.0588235294117647</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kas ir masaliņas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="515"> |
|
<prop type="lengthRatio">1.2692307692307692</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir masaliņu simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="516"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir masalu komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="517"> |
|
<prop type="lengthRatio">1.4583333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir masalu simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="518"> |
|
<prop type="lengthRatio">1.1379310344827587</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādi ir garā klepus simptomi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="519"> |
|
<prop type="lengthRatio">1.15</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is rubella treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kā ārstē garo klepu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="520"> |
|
<prop type="lengthRatio">1.0857142857142856</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="lv"> |
|
<seg>Kādas ir garā klepus komplikācijas?</seg> |
|
</tuv> |
|
</tu> |
|
</body> |
|
</tmx> |
|
|
